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Stargardt disease (STGD), a juvenile-onset form of macular dystrophy resulting in a 
severe reduction of central vision, may be inherited in either an autosomal recessive or 
autosomal dominant manner. To date the only gene found to be involved with the 
autosomal recessive form is ABCA4. Mutations in this gene are associated not only with 
STGD, but with other autosomal recessive retinal diseases. Due to the numerous 
mutations detected in ABCA4 and their associated phenotypic heterogeneity, a genotype-
phenotype model has been proposed based on the amount of ABCA4 protein activity. 
Research in the Division of Human Genetics at the University of Cape Town (UCT) has 
suggested possible ABCA4 founder mutations underlying STGD in the South African 
Caucasian Afrikaner population and has identified seven (C1490Y, R602W, IVS38-
10T>C, L2027F, V256V, G863A, and R152X) common mutations. In a cohort of 
patients affected with an ABCA4-associated retinopathy (AAR) a total of 36% were 
identified as having various bi-allelic combinations of the seven mutations.  
 
In the current study, SNaPshot PCR, allele-specific PCR (AS-PCR) and denaturing high 
performance liquid chromatography (dHPLC) analysis were used to screen for the seven 
mutations in a patient cohort and a control cohort. A high detection rate of bi-allelic 
disease-causing mutations in total of 28/72 patients (i.e. 38.89% were fully 
characterised) co firmed the designed assay to be a viable screening tool, which could 
be employed in a diagnostic setting. The detection of 12 heterozygotes in the Caucasian 
control samples (n = 269; 169 of which were specifically Afrikaner) resulted in an 
estimated background frequency of 4.46 per 100 individuals. This could be used by 
counsellors to discuss carrier risks with patients and their family members. 
Bioinformatic tools (PolyPhen, SIFT, PMUT, PANTHER PSEC, ESEfinder, and the 
BDGP Splice Site Prediction programme) revealed the predicted pathogenicity of the 
seven mutations to be as follows (in order of decreasing pathogenicity): C1490Y, 
R602W, V256V, R152X, G863A, L2027F, and IVS38-10T>C. Statistical analysis 














effect of mutation combination on phenotype (i.e. AOO/severity as a measure of clinical 
outcome).  
To improve the understanding of the genotype-phenotype correlation a larger cohort of 
South African STGD patients with the same common mutations in various combinations 
and the availability of sufficient clinical data, is required. Further investigations into the 
genotype-phenotype correlation, combined with the information on the pathogenicity of 
the mutations, could result in increased understanding regarding the impact of each 







































Chapter 1: Introduction 
 
1.1 The structure of the human eye 
 
The human eye consists of three layers: 1) the outer fibrous coat, 2) the middle vascular 
layer, and 3) the inner coat (Smit and van Dijk 1970; Grogan and Suter 1999). The 











Fig. 1.1 An illustration of a cross section of the human eye, showing important 
structural components.  
Reproduced from the website of the Steve Tatler Illustration Portfolio: 
http://illustration.stevetatler.co.uk/illustration6.htm. 
 
1) The outer fibrous coat consists of two parts, the sclera (the posterior part of the eye) 
and the cornea (the anterior part of the eye).  
 a) The sclera is a white inflexible membrane made up of connective tissue. It 
 functions to:    
  i) protect the inner parts of the eye 
  ii) provide for the attachment of the eye muscles, and 
  iii) help maintain the shape of the eye.  
 b) The cornea is a transparent layer and is a continuation of the sclera, but is 














 nerves. The transparent nature of the cornea allows for light rays to pass 
 through and reach the light-sensitive  cells. 
 
2) The middle vascular layer consists of three parts, namely the choroid, the ciliary 
body, and the iris.  
a) The choroid lines the sclera and is made up of loose connective tissue which is 
rich in blood vessels. The choroid contains dark pigments that play a role in light 
absorption. These pigments prevent the reflection of excessive rays of light 
within the eye, thus preventing blurred vision.  
 b) The ciliary body connects the iris to the choroid. It consists of circular ciliary 
 muscles, which function in controlling the curvature of the lens. 
 c) The iris forms the anterior part of the middle vascular layer, and consists of 
 a thin,  contractile curtain-like structure with a circular opening in the centre 
 called the pupil. The iris is comprised of involuntary circular and radial 
 muscle fibres, which control the size of the pupil, thereby regulating the 
 amount of light entering the eye. 
 
3) The inner coat of the eye is comprised of the retina. The retina consists of an outer 
pigmented layer and an inner neuronal layer (Fig. 1.2). 
a) The inner neuronal layer consists of five major cell types, namely:  
 i) the photoreceptor cell layer 
 ii) the horizontal cell layer 
 iii) the bipolar neuron layer  
 iv) the amacrine cell layer, and  
 v) the ganglion cell layer. 
b) The outer pigmented layer or retinal pigment epithelium (RPE) consists of a 
single layer of cuboidal cells that contain dark pigment granules, which help to 
absorb light. The RPE is situated between the outer segments of the 



























Fig. 1.2 An illustration of the retina showing the retinal pigment epithelium and 
five cell types of the neuronal layer.  
Reproduced and adapted from the website of the Med Gadget Internet Journal of emerging medical 
technologies: http://medgadget.com/archives/2006/04/nonlightsensiti_1.html.  
 
1.1.1 The retina 
 
The retina consists of an organised layer of cells that are involved in the early stages of 
the visual cascade (Fig. 1.2) (Molday 2007). The photoreceptor cell layer contains the 
receptors required for vision, namely the rods and the cones. The horizontal cell layer 
connects clusters of photoreceptor cells. The visual impulse is transmitted to the bipolar 
cells, which in turn synapse with the amacrine cells. The amacrine cells carry the 
impulse to the ganglion cells. The axons of the ganglion cells join to form the optic 
nerve. The optic nerve conducts the impulses to the brain, where they are interpreted, 
resulting in vision. The retinal region where the optic nerve leaves the eye is known as 
the blind spot as it contains no photoreceptors, hence there is no light sensitivity in this 
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1.1.1.1 The photoreceptor cells of the retina 
 
Photoreceptor cells are modified neurons that convert light rays into nerve impulses 
(Smit and van Dijk 1970; Grogan and Suter 1999). These cells consist of an outer 
segment and an inner segment, which are joined by a thin cilium (Fig. 1.3). The 
photoreceptor outer segments contain discs and are involved in the detection of light and 
in the conversion of light into electrical impulses in a process known as 
phototransduction (Molday 2007). The inner segment contains the mitochondria, 
endoplasmic reticulum, and other organelles essential for cell metabolism. The cell body 
is situated just below the inner segment. The cell body, containing the nucleus, is 
connected to the synaptic region. It is from the synaptic region of a photoreceptor cell 
that a visual impulse is transmitted to the subsequent secondary neurons in the inner 















Fig. 1.3 A diagrammatic representation of the photoreceptor cells, showing the 
gross structure of the rod and cone cells.  
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There are two types of photoreceptor cells (Grogan and Suter 1999; Smit and van Dijk 
1970): 
 Rod cells are thin and elongated and are highly concentrated in the peripheral 
 region  of the retina. The eye contains approximately 140 million rod cells. 
 The outer segment of these cells contains the visual pigment, rhodopsin.  
 Cone cells are broader and cone-shaped, and are found to be more abundant 
 in the central  region of the  retina. The eye contains approximately seven 
 million cone cells. The outer  segment of these cells contains the visual 
 pigment, iodopsin. 
 
Both the rod and cone cells are sensitive to light, with the rods having a greater 
sensitivity. Rod cells are specialised for dim light or night vision, whereas cone cells are 
specialised for bright light or day vision, and are involved in visual acuity and colour 
perception (Smit and van Dijk 1970; Molday 1998; Grogan and Suter 1999). 
 
The outer segments of rod cells consist of more than 1000 flattened discs that are 
stacked together and are surrounded by a plasma membrane (Molday 2007). In 
comparison to the rod cells, the plasma membrane of the outer segment of a cone cell 
forms a continuous folded structure with the discs. 
 
The photoreceptor cells form a functional unit with the previously mentioned RPE. The 
RPE functions to: a) absorb stray light rays, b) provide transport of substrates produced 
in the visual cycle to the photoreceptor cells, c) create a blood-retina barrier, d) renew 
the visual pigments in the photoreceptor cells, and e) phagocytose the shed outer 
segment photoreceptor cell discs (Coles 1989). The surface of the RPE contains many 
processes that expand into the spaces between the rod and cone cell outer segments. 
These processes may be involved in phagocytosis of the photoreceptor outer segments 
(Essner et al. 1978; Coles 1989). 
 
In order for photoreceptor cells to carry out their crucial function in the process of 
vision, the structure and components (visual pigments) of these cells needs to be 














phagocytosis and renewal. In rod cells, new disks are formed at the base of the outer 
segment in the cilium, while older disks are shed from the tips. The shed disks are 
released into the inter-photoreceptor space and phagocytosed by the RPE (Essner et al. 
1978; Fein and Szuts 1982; Coles 1989). A similar process exists for cone cell outer 
segments (Anderson et al. 1978). The entire outer segments of rod cells are replaced 
every eight to 14 days (Coles 1989). In cone cells, disc renewal is much slower, with the 
process taking nine months to one year. The discs from rod cells are shed in light, 
mainly after extended periods of darkness, in comparison to cone cells where the discs 
are shed during the night. 
 
1.1.1.2 The macula 
 
The retina also consists of a region called the macula lutea, more commonly known as 
the macula. The macula is an oval region situated near the centre of the retina, adjacent 
to the previously mentioned blind spot. The macula has a darker appearance in 
comparison to the retina as a whole, and consists mainly of cone cells. The macula 
contains a central pit, which is called the fovea. This central fovea is very thin and 
contains no rod cells, and is the region of highest visual acuity in the retina (Fig 1.4) 
(Smit and van Dijk 1970; Coles 1989; Grogan and Suter 1999). Numerous hereditary 
diseases affecting the macula have been identified and are characterised by loss of 
macula functioning (Weber 1998). Due to the high concentration of cone cells in this 
region of the retina, both colour and central vision is affected (Fig 1.5). These eye 
disorders are collectively known as macular dystrophy or degeneration (MD) and can be 
inherited in an autosomal dominant, autosomal recessive or X-linked manner 


























Fig. 1.4 A diagrammatic representation of the macula, showing the central fovea 
region that consists of mainly cone cells.  














Fig. 1.5 An illustration showing the loss of vision in individuals with macular 
degeneration.  
Reproduced from Healthy Fellow – Your Natural Health Critic Foundation: 
http://www.healthyfellow.com/150/vitamins-for-macular-degeneration/. 














1.2 The visual cycle 
 
The structures that form the inner lining of the human eye (the retina) play essential 
roles in the visual transduction pathway and process of vision. The photoreceptors make 
use of a chromophore, 11-cis retinal, for the absorption and processing of light via the 
visual transduction pathway (Thompson and Gal 2003). This vitamin A analog is highly 
photosensitive and is responsible for initiating the signal transduction that results in 
vision. Upon light activation the chromophore is converted to all-trans retinal. Sustained 
phototransduction, which is dependent on the replenishment of 11-cis retinal, can be 
accomplished by maintaining the cycling process of vitamin A analogs through the 
visual cycle (Fig. 1.6). The visual cycle involves the metabolism of vitamin A and the 
circulation of vitamin A analogs between the RPE and the photoreceptor cells. The 
visual cycle involves numerous specialised proteins and enzymes and begins with the 
absorption of light by the visual pigments, rhodopsin and iodopsin, in the rod and cone 
photoreceptor cells, respectively. The visual pigments are membrane proteins located in 
the outer segments of the photoreceptor cells, and contain the chromophore, 11-cis 
retinal (Thompson and Gal 2003). 
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Following light activation, all-trans retinal is released from the visual pigments. In the 
rod photoreceptor cells, all-trans retinal is converted into a product called N-
retinylidene-phosphatidylethanolamine (N-retinylidene-PE) by reacting with 
phosphatidylethanolamine (PE). The N-retinylidene-PE is transported to the surface of 
the cytoplasmic plane of the disc membrane by the retina-specific adenosine 
triphosphate (ATP)-binding cassette transporter (ABCA4), formerly known as ABCR. 
This leads to the release of all-trans retinal into the cytoplasmic space (Thompson and 
Gal 2003; Molday et al. 2009).  
 
Once in the cytoplasm, all-trans retinal is converted to all-trans retinol by an enzyme, 
all-trans retinol dehydrogenase (RDH8), and is transported to the RPE. On arrival at the 
RPE, all-trans retinol is esterified in the lipid bilayer to form all-trans retinyl esters. The 
enzyme lecithin retinol acyltransferase (LRAT) is involved in this process. This is 
followed by the generation of an 11-cis double bond in the side chain by the enzyme, 
retinoid isomerase. An RPE-specific protein, RPE65, is also needed for this reaction. 
The final aldehyde product is produced by the enzyme 11-cis retinol dehydrogenase 
(11cisRDH). This reaction is accelerated by the cellular retinaldehyde-binding protein 
(CRALBP). The 11-cis retinal leaves the RPE, passes through the subretinal region, and 
enters the outer segments of the photoreceptors. The 11-cis retinal attaches to the opsin 
proteins, and the visual pigments are regenerated (Thompson and Gal 2003; Miyazono et 
al. 2008). 
 
In cone cells the transport of vitamin A analogs resulting in the initiation of vision is 
similar. The rate of reduction of all-trans retinal to all-trans retinol is 10-40 times 
greater in cones compared to the reduction in rod cells (Miyazono et al. 2008). Studies 
conducted on cone cells suggest a faster supply of 11-cis retinal occurs for regeneration 
of the visual pigments. Numerous reports propose that cone cell visual pigments can also 
be regenerated independently from the RPE in a cone-specific pathway in Müller cells 














cells present in the inner retina that help maintain the normal functioning and survival of 
the neurons in the retina (Franze et al. 2007). 
 
1.3 ATP-binding cassette transporter family of proteins 
 
The ATP-binding cassette transporters (ABC transporters) comprise a superfamily of 
proteins that represent the largest group of membrane transporters. ABC proteins are 
found in both prokaryotic and eukaryotic organisms. These transmembrane proteins bind 
ATP, using the energy to transport a wide range of substrates, including amino acids, 
metabolites, vitamins, and steroids across cell membranes to various regions in the cell 
(Allikmets et al. 1997a; Molday 2008; Loo and Clarke 2008). Some of the ABC protein 
members transport a variety of different compounds with diverse structures, whereas 
other ABC members are specific to one substrate. Not all ABC proteins function as 
transporters however, for example, the cystic fibrosis transmembrane conductance 
regulator (CFTR) which acts as a chloride channel, and the sulfonylurea receptor (SUR 
1) which is a potassium channel regulator. To date, 49 ABC proteins have been 
identified, 19 of which have been linked to diseases (Loo and Clarke 2008). 
 
1.3.1 The basic structure of an ABC transporter 
 
ABC transporters consist of two nucleotide-binding domains (NBDs) and two 
transmembrane domains (TMDs). The NBDs or ATP-binding domains (also referred to 
as nucleotide-binding folds or NBF) are situated in the cytoplasmic region of the cell, 
and function to bind and hydrolyze ATP, thus providing the energy needed to transport 
the substrate through the membrane. Both NBDs contain sequences that are conserved 
for ATP-binding; these include the Walker A and Walker B motifs, Q-loop, LSGGQ 
signature sequence (C motif), D-loop, and H-loop. The Walker A and B motifs are a 
common feature of all ATP-requiring proteins. The C motif or linker peptide is 
characteristic of the members of the ABC superfamily. The TMDs usually consist of six 














The TMDs provide a pathway for the translocation of a compound across the membrane 
(Saurin et al. 1999; Dean et al. 2001; Molday 2007; Loo and Clarke 2008). The structure 
or composition of the TMD determines the specificity for the type of molecule(s) 
transported (Dean and Allikmets 1995). Little homology exists with respect to the amino 
acid composition of the TMDs among the various ABC transporters (Loo and Clarke 
2008).  
 
Amino acid sequence alignments of the ATP-binding domains and the organisation of 
the NBDs of the various ABC proteins, has resulted in these transporters being classified 
into subfamilies. To date seven subfamilies exist, which are labelled alphabetically from 
ABCA to ABCG (Dean and Allikmets 2001, Molday 2007). For the purpose of this 
investigation, the members belonging to the subfamily, ABCA, will be described in 
more detail. 
 
1.3.2 The ABC transporter subfamily, ABCA 
 
Members of the ABC transporter protein subfamily ABCA show a high degree of 
similarity in both sequence and structural organisation (Molday et al. 2009). This 
subfamily consists of twelve ABCA genes, divided into two groups based on gene 
structure and homology. Group one consists of the genes ABCA5, ABCA6, ABCA8, 
ABCA9 and ABCA10. Group two consists of the genes ABCA1, ABCA2, ABCA3, 
ABCA4, ABCA7, ABCA12, and ABCA13. The genes present in group one each have 38 
introns, whereas the genes in group two have 50 to 51 introns. The second group of 
genes also have longer amino terminal portions when compared to the genes in the first 
group (Dean et al. 2001; Dean and Allikmets 2001; Molday 2007; Molday et al. 2009). 
Proteins encoded by ABCA genes have been implicated in the transport of a variety of 
lipids across cell membranes. The functions of all the proteins in this subfamily have not 
been elucidated (Dean et al. 2001). However, four ABCA proteins (ABCA1, ABCA3, 
ABCA4, and ABCA12) are known to be related with different genetic diseases that are 
caused by defects in lipid transport. Lipid transport is essential as it ensures the 














genes, their chromosomal locations, and associated diseases (if known) are listed in 
Table 1.1.  
 
Table 1.1 The location and associated diseases of the twelve genes that encode the 
ABCA protein subfamily.  






ABCA1 9q31.1 Tangier disease (Rust et al. 1999) 
ABCA2 9q34  
ABCA3 16p13.3 
Respiratory distress syndrome (Cheong 
et al. 2006) 
ABCA4 1p13-21 
Autosomal recessive Stargardt disease 
(Allikmets et al. 1997a), Autosomal 
recessive retinitis pigmentosa (Rozet et 
al. 1999), Cone-rod dystrophy (Briggs 
et al. 2001) 
ABCA5 17q24  
ABCA6 17q24  
ABCA7 19p13.3  
ABCA8 17q24  
ABCA9 17q24  
ABCA10 17q24  
ABCA12 2q34 Harlequin ichthyosis (Akiyama 2006) 
ABCA13 7p11-q11  
 
1.3.3 The ABCA4 gene and protein 
 
The ABCA4 gene is located on chromosome 1, at position 1p13-21 (Kaplan et al. 1993). 
Initially it was thought that the gene comprised 21 exons, but further research revealed 














sizes range from 33 to 266 base pairs (bp), with the gene having an open reading frame 
greater than 6 800 bp (Allikmets et al. 1998). 
 
Studies utilising immunofluorescent labels have revealed the expression of ABCA4 in 
the outer segment of both the cone and rod photoreceptor cells (Allikmets et al. 1998; 
Molday et al. 2000, Molday 2007). Various reports have described ABCA4 to be an 
inward-directed retinoid flipase which functions in the removal of vitamin A analogs 
from the photoreceptor outer segments (Sullivan 2009). As mentioned previously, 
ABCA4 functions in the cycling of vitamin A analogs between the photoreceptor cells 
and the RPE surface in the retina, by transporting the compound, N-retinylidene-PE, to 
the cytoplasmic plane of the disc membrane of the photoreceptor cells (Thompson and 
Gal 2003, Molday et al. 2009). The function of ABCA4 thus appears to be to ensure the 
complete removal of all-trans retinal and N-retinylidene-PE from the outer segment disc 
membranes once light activation has occurred, leading to the continuation of the visual 
cycle (Molday et al. 2009). 
 
1.3.3.1 The structure of the ABCA4 protein 
 
The protein is comprised of 2 273 amino acids and is structurally arranged into two 
halves. Computer algorithms have been used to generate topological models of the 
protein (Bungert et al. 2001; Molday 2007). The models indicate that each half of the 
protein contains: 
 a single transmembrane segment with hydrophobic properties (designated H1 in 
the N-terminal and H7 in C-terminal half of protein) 
 a large exocytoplasmic domain (ECD) 
 a membrane-spanning domain (MSD), and 



























The N-terminal segment of the protein consists of 24 amino acids, many of which are 
positively charged lysine and arginine residues. Due to the nature of this region it is 











Fig. 1.7 An illustration of the proposed structure of the ABCA4 protein, showing 
the two exocytoplasmic domains (ECDs), two membrane-spanning domains 
(MSDs), and two nucleotide binding domains (NBDs).  
Reproduced and adapted from Bungert et al. 2001.
 
The C-terminal segment of the protein, comprised of 170 amino acids, is located 
downstream from NBD2. This C-terminal region consists of a conserved motif 
containing six amino acids, Valine-Phenylalanine-Valine-Asparagine-Phenylalanine-
Alanine (VFVNFA). Research has indicated that this conserved region is important in 
the correct folding of the ABCA4 protein (Molday 2007; Zhong et al. 2008; Molday et 
al. 2009). 
 
Studies have revealed the presence of four N-linked glycosylation sites in each half of 
the ABCA4 protein (Bungert et al. 2001; Molday 2007). The presence of these N-linked 
glycoslylation sites on both ECD1 (602 amino acids) and ECD2 (289 amino acids) has 
lead to the prediction that these domains are located on the lumen side of the membrane. 
Intra-chain disulfide bonds are also predicted due to the presence of many conserved 














amongst ECDs of various vertebrate ABCA4 proteins, has lead to investigations into the 
effect of mutations occurring in these regions (Biswas-Fiss et al. 2010). 
 
Both NBDs have approximately 140 amino acid residues, and share 35% sequence 
identity. The NBDs contain Walker A and B motifs as well as an active signature motif 
(C-loop). As mentioned previously, the Walker A and B motifs are a hallmark of ATP-
requiring proteins and C motifs are characteristic of ABC proteins (Bungert et al. 2001; 
Molday 2007).  
 
The number and identity of the transmembrane segments forming the MSDs has yet to 
be defined. Computer programs and hydropathy plots have predicted five or six 
transmembrane segments in each MSD. These membrane-spanning segments, along 
with the single, hydrophobic transmembrane segment that is situated just before each 
ECD, presumably form the binding site for substrates (Bungert et al. 2001; Molday 
2007; Molday et al. 2009).  
 
1.4 ABCA4-associated retinopathies 
 
1.4.1 Stargardt disease 
 
Stargardt disease (STGD) (OMIM: 248200) was first described by Karl Stargardt in 
1909 (Kaplan et al. 1993). In 1997 the link between STGD and the ABCA4 gene was 
published (Allikmets et al. 1997a). STGD is a juvenile-onset form of MD (Allikmets et 
al. 1997a; Lewis et al. 1999; Lorenz and Preising 2005). As mentioned previously, MD 
involves the macula which is situated in the central region of the retina and contains a 
high concentration of cone photoreceptor cells.  
 
STGD usually presents in the first or second decade of life and has an autosomal 
recessive mode of inheritance. It is one of the most frequent causes of macular 














STGD has an estimated incidence of 1 in 10 000 individuals, and is characterised by loss 
of cone cells which results in a severe reduction of central vision (Kaplan et al. 1993; 
Lewis et al. 1999; Lorenz and Preising 2005; Allikmets 2007). 
 
Clinical features of the disease include progressive bilateral degeneration of the macula 
and the RPE. The appearance of orange-yellow flecks located around the macula and/or 
midretinal periphery is a distinctive feature of STGD (Fig. 1.8) (Allikmets et al. 1997a; 
Sun and Nathans 1997). Fluorescein angiography - a test that uses fluorescein dye to 
study the blood vessels in the retina, iris, and choroid - has shown the choroid to be dark 
in many patients, which is indicative of the accumulation of lipofuscin (Allikmets 2007). 
Lipofuscin consists of a combination of different fluorescent by-products of the visual 
cycle. The exact molecules that comprise lipofuscin are not known, however a di-
retinoid-pyridinium-PE (A2E) fluorophore has been shown to be the major component. 
This fluorophore appears to have toxic effects on the RPE (Boon et al. 2008). 
 
STGD can also occur as an autosomal dominant disease (adSTGD). Three dominant loci 
have been identified on chromosomes 4, 6 and 13, respectively (Stone et al. 1994; Zhang 
et al. 1994; Kniazeva et al. 1999). The dominant form of STGD does not fall within the 









Fig. 1.8 A fundus photograph of the posterior of the eye (by focusing light through 
the front of the eye) showing the differences between a normal macula and a 
macula with STGD.  



















1.4.2 Mechanism of ABCA4 pathogenesis 
 
Protein misfolding, decreased functioning and mislocalisation due to mutations in the 
ABCA4 gene underlie ABCA4-associated retinopathies (AARs). The proposed 
mechanism of ABCA4-related pathogenesis is that retinoid products, such as all-trans 
retinal and N-retinylidene-PE, are not completely removed from the photoreceptor outer 
segment disc membrane (Fig 1.9). These two compounds react to form diretinal 
derivatives, such as di-retinoid-pyridinium-ethanolamine (A2PE). During the process of 
photoreceptor disc shedding, A2PE is ingested by the RPE in phagosomes, along with 
other retinoid compounds. These compounds fuse, resulting in the formation of 
phagolysosomes which house enzymes that are capable of degrading the photoreceptor 
outer segments. A2PE is converted to A2E, which is unable to be metabolised further. 
The inability of A2E to undergo any additional metabolism results in the accumulation 
of A2E and other retinal compounds, collectively known as lipofuscin, in the RPE 
(Molday et al. 2009). It appears that A2E has the potential to cause RPE dysfunction 
through at least two mechanisms: light-independent inhibition of lysosomal function and 
phototoxicity (Schütt et al. 2000). The buildup of toxic products can cause a loss of RPE 
function and ultimately a loss of photoreceptor cells, which leads to loss of vision 
(Molday et al. 2009). Photoreceptors and vision are lost secondary to the dysfunction 











Fig. 1.9 A proposed model for ABCA4-mediated retinal degeneration.  














1.4.3 Clinical heterogeneity of ABCA4-associated retinopathies 
 
To date ABCA4 has been the only gene found to be involved with autosomal recessive 
STGD (arSTGD) (Allikmets 2007). Despite the apparent locus homogeneity, there is 
considerable allelic and phenotypic heterogeneity. More than 500 ABCA4 mutations 
have been identified to date including single-base substitutions, duplications and 
deletions (Lewis et al. 1999; Briggs et al. 2001; Aguirre-Lamban et al. 2008). Mutations 
in the ABCA4 gene have been found to be associated not only with STGD, but with other 
RDDs including fundus flavimaculatus (FFM), cone-rod dystrophy (CRD), and 
autosomal recessive retinitis pigmentosa (arRP) (Allikmets et al. 1997a; Allikmets et al. 
1997b; Cremers et al. 1998). Research has also been conducted on the role that the 
ABCA4 gene might play in age-related macular degeneration (AMD) which is the most 
common cause of visual loss in the elderly. AMD is similar to STGD, in that it affects 
the macula. Investigations linking ABCA4 with AMD have been controversial, with 
some researchers showing no significant association (Allikmets et al. 1997b; Pennisi 
1997; Stone et al. 1998, Patel et al. 2008). Environmental risk factors, including diet and 
smoking, have also been found to be associated with AMD. 
 
FFM is clinically similar to STGD, however, it often has a later age of onset, slower 
disease progression, and a more widely spread distribution of the characteristic orange-
yellow flecks on the retina (Maugeri et al. 1999; Allikmets 2007). The terms FFM and 
STGD are often used interchangeably. 
 
CRD is characterised by a decrease in central vision, and granular changes in the 
macular RPE. In the initial stages of CRD there can be a reduction or absence of cone 
cell responses with only a slight decrease in rod cells functioning, or both photoreceptor 
cells types may be equally affected (Klevering et al. 2004). 
 
Retinitis pigmentosa (RP) comprises a group of retinal diseases characterised by the loss 
of rod photoreceptor cells. Clinical features of RP include progressive peripheral vision 
loss and night blindness (Cremers et al. 1998). RP is both clinically and genetically 














X-linked disease. There have been more than 20 genes and loci associated with RP, but 
these account for less than 50% of cases (Martinez-Mir et al. 1998). arRP is the most 
severe retinal disease associated with mutations in the ABCA4 gene. It is thought to be 
due to the complete loss of ABCA4 protein activity. Both truncating and abnormal 
splicing mutations have been found in families affected with ABCA4-associated arRP 
(Rozet et al. 1999; Wiszniewski et al. 2005). 
 
1.4.4 Genotype-phenotype models 
 
The vast array of ABCA4 mutations, along with the nature of the specific mutations or 
combination of mutations is ultimately responsible for the broad range of the phenotype. 
Different mutations, leading to an altered amino acid sequence, affect protein function in 
different ways. These mutations could result in a decrease in ABCA4 activity, or create 
a misfolded protein which could give rise to a toxic effect on a) the cell(s) involved, or 
b) the cell(s) in the vicinity. This may be a result of either the type of mutation (i.e. 
missense, nonsense, frameshift, etc) or position of mutation (Sullivan 2009). 
 
The large amount of allelic and phenotypic heterogeneity observed with ABCA4 
mutations has led to the proposal of a genotype-phenotype model (Fig. 1.10). Various 
research groups have attempted to determine the relationship between different ABCA4 
mutations and the severity of AARs. Van Driel et al. (1998) stated that most ABCA4 
mutations could be placed into different classes of severity, and that the phenotype can 
vary depending on the remaining total activity of the ABCA4 protein. The same model 
was later discussed by Shroyer et al. (1999).  
 
The proposed genotype-phenotype model states that both truncated proteins (resulting 
from the presence of null alleles) and extremely misfolded proteins are associated with 
RP and CRD. Patients who retain partial ABCA4 activity due to the presence of so-
called “milder” mutations (some nonsense and missense mutations) will develop 
arSTGD and FFM. It is hypothesised that the development of AMD in patients 




































byproducts (lipofuscin) leading to eventual photoreceptor cell loss (van Driel et al. 1998; 











Fig. 1.10 An illustration showing the proposed genotype-phenotype correlation 
model for ABCA4.  
Adapted and reproduced from: Shroyer et al. (1999). On the left ABCA4 activity is represented by the 
triangle. ABCA4 protein activity is the greatest at the bottom of the triangle, decreasing towards the top of 
the triangle. It has been proposed that arRP is a result of very low ABCA4 activity, while arSTGD has 
been proposed to result from mild ABCA4 activity. An individual with the normal amount of ABCA4 
activity does not present with any AAR. 
 
The biochemical function of the ABCA4 protein and the examination of the functional 
consequences of ABCA4 mutations (i.e. the pathogenic contribution) are important 
factors to consider in order to fully understand the proposed genotype-phenotype 
correlation (Biswas-Fiss et al. 2010; Schindler et al. 2010). In 2006, Valverde et al. 
hypothesised that both the type of ABCA4 mutation and its position, in conjunction with 
the combination of the mutant alleles, play a role in the age of onset (AOO) of visual 
impairment or deterioration (Valverde et al. 2006). Similarly, Lewis et al. (1999) used 
the AOO of visual impairment to assess the clinical severity of a pair of mutant ABCA4 
alleles. In the latter study Lewis et al. observed more frame-shift and early nonsense 

















1.5 ABCA4-associated retinopathy research in South 
Africa  
 
The implications of molecular genetic studies in diagnosing retinal diseases was realised 
in the 1980’s with the identification of a restriction fragment length polymorphism 
(RFLP) on the X-chromosome found to be linked to RP (Oswald et el. 1985). Research 
into the genetics of retinal degenerative disorders (RDDs) was initiated in the Division 
of Human Genetics at the University of Cape Town (UCT) in 1990, with the banking of 
DNA samples for both molecular genetic studies and diagnostic purposes. To date DNA 
has been obtained from 2941 individuals in 1210 families. The RDD families are 
categorised according to their clinical diagnosis or pattern of inheritance. Table 1.2 
shows the division of RDD families into STGD-affected families, families affected with 
arRP, and families affected with a macular-associated RDD, with specific focus on the 
Caucasian families for the purpose of the current study (as at May 2010). 
 








Number of Affected 
Caucasian 
Individuals 
STGD-affected 228 197 252 
arRP 89 53 73 
Macular-
associated 
323 290 315 
Other RDD 570 331 518 
Total 1210 871 1158 
 
Research in the Division of Human Genetics at UCT has suggested that there are several 
founder effects underlying STGD in the South African Afrikaner population (September 














c.1885C>T, c.6079C>T, c.768G>T, and c.454C>T were observed in affected South 
Africans at frequencies noticeably different to those found in European populations. 
Four of the mutations (c.4469G>C, c.1885C>T, c.768G>T, and c.454C>T) were found 
to be rare in European populations (Lewis et al. 1999; Maugeri et al. 1999; Maugeri et 
al. 2002; Rosenberg et al. 2007). It should be noted that more than 90% of individuals in 
the September et al. (2004) study were of Afrikaner descent. This is probably due to the 
fact that individuals affected with STGD that have been recruited into the RDD research 
program at UCT are mainly of Caucasian Afrikaner ancestry. This scenario could have 
arisen from a historical ascertainment bias, due to referrals from special schools who 
deal with visually impaired individuals or be a reflection of the high incidence in the 
population group. These schools were previously restricted to individuals of certain 
ethnic groups (September et al. 2004). 
 
The Caucasian population of South Africa originated mainly from the immigration of 
groups of individuals over the past few centuries from various European countries to 
South Africa. The Afrikaner population or Afrikaans-speaking Caucasians originated 
mainly from three countries, namely, Holland, Germany, and France (Ramesar et al. 
2001; September et al. 2004). The large number of Afrikaners affected with STGD may 
be due to a founder effect or effects resulting from the immigration of the above 
mentioned groups of individuals into the Cape Province more than 330 years ago and 
their subsequent migration between the years 1835 to 1843 further into the interior of 
Southern Africa. The movement is known as “Die Groot Trek” (Botha and Beighton 
1983; September et al. 2004). STGD is not the only heritable disease associated with the 
Afrikaner population; a very high prevalence of other genetic diseases has also been 
found in this group, including familial hypercholesterolemia and variegate porphyria 
(Gevers et al. 1987).  
 
Traditional mutation screening methods have been expensive and laborious as the 
ABCA4 gene is large in size (50 exons). Thus, in order to facilitate rapid, cost effective 
screening of large numbers of DNA samples from subjects with suspected AARs, Asper 
Ophthalmics in Estonia developed the ABCR400 microarray chip (Jaakson et al. 2003; 














ABCA4 gene (http://www.asperbio.com). Investigations into the efficiency of the 
ABCR400 array revealed it to be more than 98% effective in identifying variants that 
were already present on the chip (Jaakson et al. 2003). Of all possible alleles associated 
with the ABCA4 gene, the microarray identified 54-60% in patient screening studies. It 
should be noted that since the chip carries out direct sequencing at each of these queried 
positions, it does allow for the detection of novel variants at all positions included on the 
microarray. The ABCR400 microarray chip is constantly being expanded, with novel 
changes or mutations being added regularly (Jaakson et al. 2003).  
 
The ABCR400 microarray was designed by using the arrayed primer extention (APEX) 
technology. This technology is essentially a direct sequencing reaction using a solid base 
for support. Briefly, this method involves the use of sequence-specific oligonucleotides 
which have been modified at their 5’ end. These oligonucleotides are arrayed onto a 
glass slide and are usually designed in such a way that their 3’ end flanks the variable 
site of interest. Specific target nucleic acids are prepared by the polymerase chain 
reaction (PCR) and annealed to the oligonucleotides on the glass slide. Subsequently, the 
addition of a DNA polymerase enzyme allows the sequence-specific extension of the 3’ 
ends of primers with fluorescently-labelled dideoxynucleotide triphosphates (ddNTPs) 
(Jaakson et al. 2003).  
 
ABCR400 genotyping in a South African cohort of RDD-affected individuals conducted 
by the Division of Human Genetics at UCT led to the detection of causative mutations in 
over 60% of the cohort (Roberts et al. 2009). The cohort consisted of 132 DNA samples 
from patients with a clinical diagnosis of STGD, FFM, or CRD. The majority of the 
cohort consisted of individuals diagnosed with STGD. The DNA samples of individuals 
were sent to Asper Ophthalmics in Estonia for genotyping on the microarray in order to: 
1) validate partial results already obtained in the Division of Human Genetics at UCT 
(with the objective of obtaining both causative mutations), and 2) identify the two 
causative mutations in samples that had not been previously investigated. The screening 
results revealed that of the 132 samples tested, 85 were found to carry two mutations, 30 
were found to carry one mutation, and 17 were found to carry no mutations. However, in 














where two mutations were identified were verified using locally developed diagnostic 
assays. These assays revealed only 80 individuals with bi-allelic causative mutations, 
which thus emphasises the importance of validating the microarray results. To date a 
total of 181 DNA samples from individuals affected with an AAR have been sent for 
ABCR400 microarray screening; of which 100 samples have been completely 
characterised (i.e. bi-allelic mutations identified). In a total of 66 of these samples, both 
mutations were part of the seven most prevalent mutations (unpublished data). 
ABCR400 genotyping has resulted in a total of 67 different mutations being identified in 
the South African cohort (unpublished data). 
 
In addition to the results obtained by September et al. (2004), the results acquired from 
the microarray screening identified an additional two mutations (c.5461-10T>C and 
c.2588G>C) that were found to also occur at a high frequency in affected individuals. 
Again, the majority of these mutations have been found in Caucasian individuals of 
Afrikaner descent. Seven of the 67 mutations were found to account for approximately 
70% of all ABCA4 mutations detected (unpublished data). These seven ABCA4 
mutations are listed in the Table 1.3 below.  
 
Table 1.3 The seven common ABCA4 mutations in South African patients with 
STGD. 
 
For the purpose of the current study, the seven mutations investigated will be referred to 










c.4469G>A C1490Y Exon 30 missense Zhang et al. (1999) 
c.1885C>T R602W Exon 13 missense Webster et al. (2001)  
c.6079C>T L2027F Exon 44 missense Webster et al. (2001)  
c.768G>T V256V Exon 6 splice site Webster et al. (2001)  
c.5461-10T>C IVS38-10T>C Intron 38 unknown Klevering et al. (2005) 
c.2588G>C G863A Exon 17 missense Maugeri et al. (1999) 














1.6 Aims and objectives of this project 
 
Previous attempts at defining the genotype-phenotype correlation have been restricted 
by (i) limited number of families with the same mutations, (ii) limited number of 
families with the same combination of mutations for comparison, and (iii) inadequate 
phenotypic/ophthalmologic data. The presence of a significant cohort of South African 
STGD patients with the same common mutations in various combinations could allow 
the improved understanding of the relationship between mutation combination and 
patient prognosis. The investigation of the genotype-phenotype correlation, together 
with pathogenicity predictions of the mutations involved, could lead to increased 
knowledge regarding the impact of each mutation, thus enhancing the clinical utility of 
identifying ABCA4 mutations. 
 
The aim of this project is to investigate the seven common ABCA4 mutations in South 
African individuals. The objectives will be to 1) determine the carrier frequencies of the 
mutations in a control cohort of Caucasian individuals, particularly those of Afrikaner 
descent, 2) assess the pathogenicity of the mutations using bioinformatic tools, and 3) 
gain more insight into the genotype-phenotype correlation of ABCA4 and manifestations 
of STGD disease. 
 
The proposed experimental plan is as follows: 
 
1. To create reproducible, sensitive assays to detect the seven most common 
ABCA4 mutations, using a multiplex SNaPshot reaction and allele-specific PCR 
(AS-PCR) assays.  
2. To use the designed assays to screen for the seven ABCA4 mutations in 72 
unrelated individuals with STGD who have not been previously analysed with 















3. To use the designed assays to screen 269 Caucasian controls (169 of which are of 
Afrikaner ancestry) for the seven ABCA4 mutations, to determine the frequency 
at which these mutations occur in the control population.  
4. To use bioinformatic tools to investigate the functionality of each of the seven 
ABCA4 mutations individually, in order to determine the predicted pathogenicity 
of each mutation. 
5. To combine the results obtained from this screening with results from previous 
South African ABCA4 mutation screening studies and to identify individuals with 
two of the same (homozygous) or two different (compound heterozygous) 
common mutations. The mutation combination will be correlated with the 
clinical data available for each affected individual. The clinical information will 
include: date of birth, gender, ethnicity, AOO, age at examination (progression), 
visual acuity, doctor’s diagnosis, and any other clinical details available. 
Statistical analysis will be used to investigate the influence of the ABCA4 
mutations on the clinical phenotype of the STGD individuals (genotype-
phenotype correlation). 
 
The assays designed for this project will utilise the existence of common mutations in 
South Africans and may be employed in the future to target or direct testing for both 
research and diagnostic purposes. This could potentially reduce the testing costs to the 
research laboratory and patient, respectively. Determining the carrier frequencies for the 
seven common ABCA4 mutations in the South African population may be useful in 























Chapter 2: Materials and Methods 
 
2.1 Cohort selection  
 
The individuals selected for this project were divided into two groups, the patient/subject 
cohort and control cohort. 
 
The patient cohort comprised of subjects affected with AARs namely STGD, FFM, 
CRD, and arRP. This cohort was further sub-divided into:  
i) 86 subjects from 66 families who, through previous analysis using the 
ABCR400 microarray chip (Asper Ophthalmics in Estonia), had been 
shown to carry two of the seven common ABCA4 mutations. A total of 73 
individuals were diagnosed with STGD, three with FFM, eight with 
CRD, and two with arRP. All subjects were of Caucasian ancestry. 
ii) 72 subjects who were unrelated and who had not been previously 
screened using the ABCR400 microarray chip. A total of 70 individuals 
were diagnosed with STGD and two individuals with CRD. A total of 60 
individuals were Caucasian, eight were of Mixed Ancestry, three were 
Indian, and one was indigenous Black African.  
The available demographic and clinical information of each patient included gender, 
ethnicity, date of birth, AOO, the ophthalmologic diagnosis, age at examination, and full 
details of visual acuity. This information was collated in order to be used for the latter 
part of this study (genotype-phenotype correlation). 
 
Screening for the seven common ABCA4 mutations was performed on patient DNA 
samples where patients had been recruited already for the broader RDD project. 
Informed consent was obtained from patients according to the tenets of the Declaration 
of Helsinki (2008). The DNA consent forms (Appendix 1) and patient information 














Ethics Committee (UCT URC REC REF 168/99 amended 2003 and 2005). Ethics 
approval for this current study was also obtained, and subsequently revised and renewed 
until 15 March 2011 (UCT URC REC REF 186/2009).  
 
The control cohort comprised of 269 individuals of Caucasian ethnicity who 1) had not 
been specifically clinically assessed for the presence of RDDs, and 2) had not been 
questioned regarding a family history of RDDs (but were not part of the RDD research 
cohort). A total of 169 individuals were specifically of Afrikaner descent. Individuals 
were defined as being Afrikaner on the basis of their family name and stated ancestry 
upon recruitment. Furthermore, for 119 of these 169 individuals, family pedigrees 
indicated that this sub-cohort has been in South Africa for two or more generations. The 
pedigrees verified Afrikaner descent, showing the individuals to be of European origin, 
particularly North Western, with distinct input from the Dutch, German, and French 
population groups. 
 
2.2 Determination of DNA integrity 
 
Due to the fact that they can deteriorate over time, the quality and quantity of the DNA 




The concentration of each DNA sample was measured using a Nanodrop 1000 
Spectrophotometer (Nanodrop Technologies Inc., Wilmington, USA). The samples were 
then diluted to a working concentration of 100ng/μl using SABAX distilled H2O (dH2O) 
















2.2.2 Agarose gel electrophoresis 
 
Appendix 2 contains all recipes used for agarose gel electrophoresis. 
 
In order to assess whether any DNA samples had compromised integrity, 200ng of 
diluted DNA samples together with 3μl of loading dye were loaded onto 1% agarose 
gels that contained ethidium bromide (EtBr) (0.6μg/ml) (Appendix 2). Agarose gel 
electrophoresis was conducted at a voltage of 160 volts (V) for 20 minutes (min). 
 
The DNA was visualised by ultraviolet transillumination using the Uvipro Gold 
transilluminator (UVITec, Cambridge, UK). A DNA sample that appears as a smear is 











Fig. 2.1 A digital photograph of a 1% agarose gel, showing an example of DNA 
sample integrity, visualised with EtBr.  
Lanes 1, 2, and 5 contain DNA samples with a tight, bright band near the top of the agarose gel, indicating 
intact DNA. By comparison, lanes 3 and 4 contain DNA samples appearing as a smear down the agarose 






















2.3 Primer design 
 
2.3.1 Gene annotation 
 
The genomic sequence of ABCA4 was obtained from two websites: Ensembl 
(http://www.ensembl.org/index.html) and National Center for Biotechnology 
Information (NCBI) (http://www.ncbi.nlm.nih.gov/). The reference number for the 
ABCA4 genomic sequence is ENSG00000198691 for the Ensembl website and 
NG_009073.1 for the NCBI website. The gene sequence was annotated using the Annot 
v9 programme designed by Dr G. Rebello (2006). This gene an otation programme 
indicates the locations of the intron-exon boundaries as well as the single nucleotide 
polymorphisms (SNPs) in the genomic sequence. The positions of the mutations of 
interest were identified manually. Appendix 3 contains sequence annotations for the 
seven exons interrogated in the current study, indicating the locations of the seven 
mutations. 
 
2.3.2 Primer information 
 
The primers were synthesized using the Oligo 1000M DNA Synthesizer v4.20 
(Beckman Instruments Inc., Department of Molecular and Cell Biology, UCT). Working 
stocks of 20μM (10μM for the internal SNaPshot primers) were diluted from the primer 
stock concentrations using dH2O (Adcock Ingram, Johannesburg, SA). The diluted 
primers were stored at 4°C or -20°C. In the case of the internal SNaPshot primers, 
following their synthesis each primer was purified using high performance liquid 

















2.3.3 External primer design 
 
Seven forward and reverse primer sets had been designed to amplify the exons 
containing the mutations of interest in the ABCA4 gene in a PCR (Table 2.1). These 
external primers had been previously designed by other researchers and stored in the 
Division of Human Genetics at UCT. Standardly, primers were designed flanking exons, 
at least 20bp from intron-exon boundaries, having a length of approximately 18 to 22 
nucleotides. In addition, primers were designed to have a melting temperature (TM) of 
between 50°C and 60°C with both forward and reverse primer pairs having a similar TM, 
to possess a maximum of three nucleotide repeats (max poly X), and to have a molar 
percentage of guanine (G) and cytosine (C) nucleotides (GC content) approaching 50%. 
 
The programmes used to design the external PCR primers were: 
i. Primer 3 (Whitehead Institute for Biomedical Research, 2004) 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)  
This web-based programme was used to select adequate primers from an input 
sequence. 
ii. IDT (integrated DNA technologies) SciTools OligoAanalyzer 3.0 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) 
This web-based programme was used to analyse the designed primers for the 
formation of any possible secondary structures such as hairpins, homodimers, 
and heterodimers. 
iii.  NCBI BLAST (Bethesda, USA)  
 (http://www.ncbi.nlm.nih.gov/) 
This web-based programme was used to identify any genomic regions found to 
be similar to the sequence of the designed primers. Primers showing a great 

















Table 2.1 Information pertaining to the primers used to amplify the exons 














5 c.454C>T R152X 
Sense 19 5’ -gacccatttccccttcaac- 3’ 
Antisense 18 5’ -aggctgggtgcttccctc- 3’ 
6 c.768G>T V256V 
Sense 19 5’ -ggtgtctttcctaccacag- 3’ 
Antisense 20 5’ -aggaatcaccttgcaattgg- 3’ 
13 c.1885C>T R602W 
Sense 19 5’ -agctatccaagcccgttcc- 3’ 
Antisense 19 5’ -ccattagcgtgtcatggag- 3’ 
17 c.2588G>C G863A 
Sense 21 5’ -ctgcggtaaggtaggataggg- 3’ 
Antisense 21 5’ -cacaccgtttacatagagggc- 3’ 
30 c.4469G>A C1490Y 
Sense 19 5’ -gtcagcaactttgaggctg- 3’ 
Antisense 18 5’ -tccctctgtggcaggcag- 3’ 
39 c.5461-10T>C IVS38-10T>C 
Sense 18 5’ -gccccacctgctgaagag- 3’ 
Antisense 18 5’ -tcccagctttggacccag- 3’ 
44 c.6079C>T L2027F 
Sense 20 5’ -gaagcttctccagccctagc- 3’ 
Antisense 20 5’ -tgcactctcatgaaacaggc- 3’ 
 
2.3.4 SNaPshot primer design 
 
SNaPshot primers were designed to bind one base pair away from the mutation of 
interest following the primary PCR using external primers (ABI PRISM® SNaPshot
™
 
Multiplex Kit Protocol, Applied Biosystems). Only one primer is required to be 
designed per mutation for a SNaPshot reaction. The primer can either be designed to the 
sense or antisense strand of the DNA sequence, depending on i) whether a single 
nucleotide polymorphism (SNP) is present in the nucleotide sequence to which the 
designed primer would bind and ii) which strand shows better results based on the web-
based primer analysis programmes. A SNaPshot primer should be on average 25bp in 
length. However, in order to design primers to be used in a multiplex SNaPshot reaction, 
the SNaPshot primers need to differ by at least four to six nucleotides to allow 
distinction between the final SNaPshot products. Modification of the length of a primer 














random nucleotides that will not interfere with primer binding and specificity (Table 
2.2). 
 
The programmes used to design the internal SNaPshot primers were:  
i. IDT SciTools OligoAnalyzer 3.0 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) 
This web-based programme was used in the same manner as in the design of the 
external primers for a regular PCR reaction. This programme analyses the primer 
sequences for possible secondary structure formation, such as hairpins, 
homodimers, and heterodimers. 
 
ii. Local BLAST application in BioEdit Sequence Alignment Editor 7.0.5.2 (Hall 
1999) 
This analysis programme was used to align the chosen SNaPshot primer 
sequence with the resulting amplified region from the PCR reaction using 
external primers. This was performed in order to exclude primers showing non-
specific homology with other regions in the primary amplicon. In order to assess 
primers to be used in a multiplex SNaPshot reaction, a local database, which 
contains the nucleotide sequences of each primary amplicon, is created in 
BioEdit. Each designed SNaPshot primer is then aligned to each amplicon in the 
local database, ensuring that there is no non-specific binding of the primers to the 
other amplicons in the multiplex SNaPshot reaction. 
 
iii. AutoDimer 1.0. (Vallone and Butler 2004) 
(http://www.cstl.nist.gov/biotech/strbase/AutoDimerHomepage/AutoDimerProgr
amHomepage.htm)  
For primer design for a multiplex SNaPshot reaction, AutoDimer was used to 
align each designed internal SNaPshot primer against one another. An input file 
containing the sequences of all the SNaPshot primers was created and this was 
examined in the AutoDimer programme with a minimum score requirement of 














sequence interactions are stored to the output file. Thus, an interaction between 
two primers that has a score less than the specified minimum score requirement 
will not be displayed in the programme. Ideally, a SNaPshot primer should not 
bind to the other SNaPshot primers at more than four consecutive nucleotide 
positions. Specifically, a SNaPshot primer should not bind to another SNaPshot 
primer on their 3’ end, in order to avoid non-specific single base extention of the 
primer. In the case of the addition of random nucleotide tails, AutoDimer was 
used to investigate the acceptability of the designed SNaPshot primers both with 
their additional random nucleotide tails and without the random nucleotide tails. 
 
 
Table 2.2. Information pertaining to the SNaPshot primers designed to be used for 


























13 c.1885C>T R602W Antisense 34 
5' -tgttccagtgccacg 
aacccgccccagatgtacc- 3' 
30 c.4469G>A C1490Y Antisense 32 
5' -cttcgtggttac 
tgagcttctccctggtgctg- 3' 
39 c.5461-10T>C IVS38-10T>C Sense 37 
5' -ccgatgtagttga 
ccccgtttccaacagtcctacttc- 3' 
44 c.6079C>T L2027F Antisense 41 
5' -tactctggatcttagta 
ggtaaagatgttctcgtcctgtga- 3' 
*The nucleotide sequence written in bold is the sequence designed to bind complementary to the genomic 






















2.3.5 Allele-specific primer design 
 
2.3.5.1 General allele-specific primer design 
 
The allele-specific primers had been previously designed by other researchers and stored 
in the Division of Human Genetics at UCT. Allele-specific primer design involves 
creating one mutation-specific and one wild-type specific primer (Table 2.3).  
 
Table 2.3. Information pertaining to the primers designed to be used for AS-PCR 














5 c.454C>T R152X 




17 c.768G>T G863A 




R152X-Rc: The AS-PCR primer designed specifically to bind to the nucleotide, cytosine (C), when exon 
5 does not contain the R152X mutation, and is therefore known as the wild type primer. R152X-Rt: The 
AS-PCR primer designed specifically to bind to the nucleotide, thymine (T), when exon 5 contains the 
R152X mutation, and is therefore known as the mutation-specific primer. G863A-Rc: The AS-PCR 
primer designed specifically to bind to the nucleotide, cytosine (C), when exon 17 does not contain the 
G863A mutation, and is therefore known as the wild type primer. G863A-Rg: The AS-PCR primer 
designed specifically to bind to the nucleotide, guanine (G), when exon 17 contains the G863A mutation, 
and is therefore known as the mutation-specific primer.  
*The nucleotide sequence written in bold is the sequence designed to bind complementary to the genomic 
DNA sequence. The nucleotide sequence not written in bold is the random nucleotide tail added to the 
primer sequence. 
 
Both the mutation-specific and wild-type primers were designed with their most 3’ 
nucleotide being complementary to the mutant nucleotide or wild type nucleotide, 
respectively (Hoti et al. 2009). Random nucleotides shown not to interfere with primer 
binding and specificity were added to one or both primers to allow for size-based 
differentiation between alleles with and without a mutation. Both mutation-specific and 
wild-type primers are designed to the same strand of the DNA sequence. These primers 















i) the mutation involved, since certain 3’ mismatches affect PCR 
differently. G:T mismatches more tolerable in comparison to other 
mismatches, and therefore should not be used in allele-specific PCR (AS-
PCR) (Kwok et al. 1994).  
ii) whether a SNP is present in the nucleotide sequence to which the 
designed primer would bind.  
iii) which strand shows better results based on the web-based primer analysis 
programmes.  
Once the allele-specific primers have been designed, the external primer is chosen. The 
external primer binds on the opposite strand to the one on which the mutation-specific 
and wild-type primers bind in order to obtain the appropriate allele-specific 
amplification. The suitability of the three primers (mutation-specific primer, wild type 
primer, and external primer) for use in an AS-PCR is determined using some of the 
programmes used for external primer design and SNaPshot primer design.  
 
The programmes used to design primers for AS-PCR were:  
i. NCBI Blast. (http://www.ncbi.nlm.nih.gov/), and 
ii. AutoDimer 1.0.  
NCBI Blast was used in the same way as for external primer design, identifying any 
genomic regions found to be similar to the sequence of the primers. If a great amount of 
non-specificity was identified, the primers were excluded. Autodimer was used in the 
same way as for internal SNaPshot primer design.  In AutoDimer, the primers designed 
to be used for the AS-PCR were aligned against one another. This was conducted for the 
primers with and without their random nucleotide tails. 
 
2.3.5.2 Allele-specific primer design using locked nucleic acids 
 
In cases when allele-specific PCR (AS-PCR) was not specific, allele-specific primers 
containing a locked nucleic acid (LNA) was used. A LNA is a DNA analog, possessing 














AS-PCR (Mouritzen et al. 2003). However, DNA sequences that contain a LNA 
nucleotide display a much higher affinity and specificity to bind to its complementary 
DNA sequence in comparison to a DNA sequence with no LNA residue. This appears to 
be due to a change in the interaction between the enzyme, DNA polymerase, and the 
LNA nucleotide which has a much more rigid structure (Latorra et al 2003a). In allele-
specific primers a LNA is incorporated on the 3’ end of the primer sequence, which 
replaces both the wild type and mutant-specific nucleotides. These primers were 
designed using the same procedure as described for general allele-specific primer 
design.  
 
2.4 Detection of the seven ABCA4 mutations 
 
2.4.1 Polymerase chain reaction 
 
PCR was used in order to amplify the regions surrounding the seven mutations of 
interest. These reactions were performed on the GeneAmp® PCR System 9700 (Applied 
Biosystems, California, USA), PXE 0.2 Thermocycler (Applied Biosystems, California, 
USA) or PX2 Thermocycler (Thermohybaid, Middlesex, UK). 
 
The optimisation of amplification of the seven genomic regions, each one containing one 
mutation, included:   
(i) a temperature gradient - conducted on PX2 Thermocycler (Thermohybaid, 
Middlesex, UK), and  
(ii) a magnesium titration. 
 
i. Temperature gradient.  
This involved setting up a PCR with primer annealing temperatures (Ta) that 














annealing temperature at which the designed external primers would optimally 
anneal to the genomic DNA, in order to obtain the best product yield. A higher 
annealing temperature, leads to increased primer specificity.  
 
ii. Magnesium titration.  
This involved the use of different magnesium chloride (MgCl2) buffers from the 
PCR optimization kit (Roche Diagnostics GmbH, Mannheim, Germany). A 
MgCl2 titration was used to determine the magnesium concentration at which the 
primers anneal best to the genomic DNA. Generally, a decreased concentration 
of magnesium leads to the increase in PCR specificity, thus helping to decrease 
non-specific primer annealing. A magnesium titration was conducted in order to 
optimise a multiplex PCR for the amplification of four exons of the ABCA4 gene, 
namely 13, 30, 39, and 44. The expected product size for each exon was 267bp, 
286bp, 245bp, and 287bp, respectively (Fig. 2.2). 
 
 
Although a MgCl2 titration was performed in order to optimise a multiplex PCR for the 
amplification of four exons of the ABCA4 gene, in most cases only three PCR products 
instead of the expected four were visualised by agarose gel electrophoresis. The 
magnesium titration in this case was not entirely successful for the optimisation of the 
multiplex PCR. This resulted in the attempted single multiplex PCR being separated into 







































Fig. 2.2 A digital photograph of a 2% agarose gel showing an example of a 
MgCl2 titration conducted for optimisation of a multiplex PCR including 
exons 13, 30, 39, and 44, visualised with EtBr.  
Lane M - GeneRuler™ 100bp Plus DNA ladder (Fermentas Life Sciences, Hanover, USA); lane 
1 - 1.0mM; lane 2 - 1.5mM; lane 3 - 2.0mM; lane 4 – 2.5mM; lane 5 - 1.0mM; lane 6 - 1.5mM; 
lane 7 - 2.0mM; lane 8 - 2.5mM; lane 9 - 1.0mM; lane 10 - 1.5mM; lane 11 - 2.0mM; lane 12 - 
2.5mM; lane 13 - 1.0mM; lane 14 – 1.5mM; lane 15 – 2.0mM; and lane 16 - 2.5mM; lane WC – 
Water control. Lanes 1, 5, 9, and 13, containing a MgCl2 concentration of 1.0mM at all four pH 
values, yielded no PCR product. Lanes 4, 8, 12, and 16, containing a MgCl2 concentration of 
2.5mM all four pH values, yielded three PCR products. The best PCR products were seen in lane 
16, and this buffer was chosen to be used for optimisation of the multiplex PCR for the 
amplification of the four exons. 
 
2.4.1.1 PCR conditions 
 
PCR was generally conducted in a 25μl reaction volume using 200μM deoxynucleotide 
triphosphates (dNTPs) (Bioline, Michigan, USA), 1X reaction buffer containing 1.5mM 
MgCl2 (Colourless GoTaq
TM
 Reaction Buffer, Promega, Madison, USA), 0.5 units (U) 
GoTaq
®
 DNA polymerase (Promega, Madison, USA), 10pmol of each external primer 
(sense and antisense), and 100ng or 200ng of genomic DNA. The remaining volume was 
made up by using SABAX dH2O (Adcock Ingram, Johannesburg, SA). 
pH 8.3 
M    1     2     3    4     5    6    7     8     9   10   11  12   13  14  15   16  WC 















The general PCR thermal cycling conditions included an initial denaturation step at 
94°C for 3 min, followed by 30 cycles at 94°C for 30 seconds, Ta for 30 seconds, and 
72°C for 40 seconds, followed by a final elongation step at 72°C for 5 min. 
 
The alterations made to either the PCR components or cycling conditions in order to 
obtain optimal PCR products are listed below: 
1. Amplification of the exons containing four of the seven mutations of interest 
were conducted in two multiplex PCR reactions. One multiplex reaction 
amplified exons 30 (containing the C1490Y mutation site) and 39 (containing the 
IVS38-10T>C mutation site). The second multiplex reactio  amplified exons 13 
(containing the R602W mutation site) and 44 (containing the L2027F mutation 
site) (Fig. 2.3). The PCR components and cycling conditions for both multiplex 
reactions were the same. PCR was performed using 2.5mM MgCl2 (pH 9.2) 
(Roche Diagnostics GmbH, Mannheim, Germany), 3pmol of each external 
primer (sense and antisense for each mutation in the multiplex), and 200ng 
genomic DNA. The cycling conditions included an initial denaturation step at 
94°C for 3 min, followed by 28 cycles at 94°C for 30 seconds, 63°C for 30 
seconds, and 72°C for 40 seconds, followed by a final elongation step at 72°C for 
5 min. 
2. PCR was performed using 200ng genomic DNA for the amplification of exon 6 
(containing the V256V mutation site). The cycling conditions included an initial 
denaturation step at 94°C for 3 min, followed by 30 cycles at 94°C for 30 
seconds, 57.9°C for 30 seconds, and 72°C for 40 seconds, followed by a final 






























Fig. 2.3 A digital photograph of a 2% agarose gel showing the products of 
two multiplex PCR’s, visualised with EtBr.  
Lane M represents the GeneRuler™ 100bp Plus DNA ladder (Fermentas Life Sciences, Hanover, 
USA), Lane A represents the first of two multiplex PCRs, Lane B represents the second of the 
two multiplex PCRs, and Lane W represents the water control. The 287bp, 286bp, 267bp, and 
245bp products are representative of the amplified exons 44 (L2027F), 30 (C1490Y), 13 
(R602W), and 39 (IVS38-10T>C), respectively. 
 
 
3. The detection of the G863A mutation in exon 17 was performed using an AS-
PCR. Optimised conditions included 10pmol forward external primer, 15pmol 
G863A-Rc primer, 5pmol G863A-Rg primer, and 200ng genomic DNA. The 
cycling conditions included an initial denaturation step at 94°C for 3 min, 
followed by 35 cycles at 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 
40 seconds, a final elongation step at 72°C for 5 min, followed by an additional 
denaturation step 95°C for 5 min. On completion of the PCR, the products were 
placed directly on ice for 5 min. These two additional steps (additional 5 min 
denaturation and snap-freeze step) were added to reduce the non-specific binding 
initially visualised by agarose gel electrophoresis. 
4. Initially, numerous attempts were made to optimise an AS-PCR to detect the 
R152X mutation in exon 5, however they all proved to be unsuccessful. 
Optimisation attempts included the use of temperature gradients, magnesium 
gradients, DMSO gradients, glycerol gradients, and the replacement of the 3’ 
nucleotide in the mutation-specific and wild-type primer sequences with a LNA 





















of a normal DNA residue into the primer appears to result in a much higher 
binding affinity and specificity of the primer to its complementary DNA 
sequence (Latorra et al 2003b). As a result of unsuccessful AS-PCR 
optimisation, basic PCR (with no LA residue) was performed to amplify exon 5 
using 100ng genomic DNA. The cycling conditions involved an initial 
denaturation step at 94°C for 3 min, followed by 28 cycles at 94°C for 30 
seconds, 60°C for 30 seconds, and 72°C for 40 seconds, followed by a final 
elongation step at 72°C for 5 min. 
 
The PCR products obtained from the two multiplex PCR reactions were electrophoresed 
on a 2% agarose gel. The PCR products for exons 5 and 6 were electrophoresed on a 
1.5% agarose gel, and visualised with EtBr (Results not shown). A GeneRuler
™
 100bp 
Plus DNA ladder (Fermentas Life Sciences, Hanover, USA) was used to ensure that the 
correct PCR product size was obtained for each sample (Appendix 2). The PCR products 
obtained from the AS-PCR for exon 17 were not electrophoresed on an agarose gel as 
their product size difference was only 10bp. Instead, the products obtained from the AS-
PCR for the detection of the G863A mutation in exon 17 were resolved by denaturing 
HPLC (dHPLC) using size-based separation. 
 
2.4.2 SNaPshot reaction 
 
SNaPshot PCR is used as a form of SNP genotyping and is essentially an adaptation of 
the basic PCR procedure, requiring a template, primers, Taq polymerase, and reaction 
buffer. The SNaPshot method involves an initial primary PCR to amplify the region that 
contains the SNP or mutation of interest. The SNaPshot reaction uses PCR product as 
the template, in comparison to DNA in a normal PCR, and a single primer (forward or 
reverse internal primer) instead of a pair of primers (forward and reverse external 
primers). Instead of incorporating dNTPs, SNaPshot utilises the incorporation of 
fluorescently labelled ddNTPs, allowing the single base extension on the 3’ end of the 
internal SNaPshot primer (ABI PRISM® SNaPshot
™
















The results can be viewed using the Applied Biosystems (ABI) 3100 Genetic Analyser 




 Multiplex Kit 
Protocol, Applied Biosystems). Each of the four ddNTPs that are incorporated in the 
SNaPshot reaction are labelled with different fluorescent dye (Table 2.4). Therefore, 
depending on which ddNTP is incorporated, peak colours specific for each ddNTP will 
be used in the data analysis. 
 
Table 2.4 A table containing a list of the fluorescently labelled dyes for each 
ddNTP, as well as the colour observed during data analysis. 
Incorporated 
ddNTP 
Name of Fluorescent Dye 
Label 
Colour of the Analysed 
Data 









2.4.2.1 Primary PCR purification 
 
As described previously, two multiplex primary PCR’s were conducted in order to 
amplify four exons, each of which contained a mutation site of interest. One multiplex 
reaction amplified exons 30 (containing the C1490Y mutation site) and 39 (containing 
the IVS38-10T>C mutation site). The second multiplex reaction amplified exons 13 
(containing the R602W mutation site) and 44 (containing the L2027F mutation site).  
The PCR products obtained from the two multiplex PCR reactions were pooled using 
equal volumes of each prior to purification treatment.  
 
Following the primary PCR, the obtained amplified products were purified using a 
shrimp alkaline phosphatase (SAP) (Promega, Madison, USA) and Exonuclease I (E. 














used to remove the remaining dNTPs and primers that were not depleted during the 
primary PCR step. The SAP (Promega, Madison, USA) functions in the 
dephosphorylation of phosphates on the 5’ end of DNA sequences 
(http://www.promega.com/catalog/catalogproducts.aspx?categoryname=productleaf_147
8). Exo I (New England Biolabs Inc., USA) functions in a 3’ to 5’ direction and is 
involved in removing nucleotides from the remaining single-stranded DNA sequences, 
therefore enhancing the degradation of the external primers in the obtained in the PCR 
mixture (http://www.neb.com/nebecomm/products/productm0293.asp). 
 
This post-PCR purification was conducted in a 10μl and 20μl reaction volume for 
multiplex and single-plex reactions, respectively. Single-plex reactions were set-up 
when the multiplex reaction was unsuccessful. A 10μl Multiplex reaction volume 
consisted of 2.5U of SAP (Promega, Madison, USA) and 2U of Exo I (New England 
Biolabs Inc., USA), with the remaining volume being the pooled multiplex PCR 
products. A 20μl single-plex reaction volume consisted of 1.5U of SAP (Promega, 
Madison, USA), 1U of Exo I (New England Biolabs Inc., USA), 5μl PCR product, with 
the remaining volume being made up using SABAX dH2O (Adcock Ingram, 
Johannesburg, SA).  
 
The primary PCR purification procedure involved thermal cycling conditions at 37°C for 
one hour, followed by an enzyme inactivation step at 75°C for 15 min.  
 
2.4.2.2 SNaPshot PCR conditions 
 
Following primary PCR purification, a SNaPshot mutiplex reaction was conducted using 
all four SNaPshot primers, for the detection of C1490Y, IVS38-10T>C, R602W, and 
L2027F mutations. The four SNaPshot primers were pooled in an empirically 
determined ratio of 0.2:2:2:0.5 for R602W, C1490Y, IVS38-10T>C, and L2027F, 
respectively. The optimised amount of each primer included in the SNaPshot reaction 















Multiplex SNaPshot PCR was conducted in a reaction volume of 10μl, consisting of 5μl 
pooled, purified PCR product, 1μl pooled SNaPshot primers (using a working stock of 
10μM), and 1μl SNaPshot Multiplex Ready Reaction Mix (Applied Biosystems, 
Warringon, UK). The remaining volume was made up by using SABAX dH2O (Adcock 
Ingram, Johannesburg, SA). A negative control consisting of a reaction in SABAX 
dH2O (Adcock Ingram, Johannesburg, SA) and no pooled, purified PCR product was 
included in each multiplex SNaPshot PCR set-up. Single-plex SNaPshot reactions were 
conducted for four samples known to be heterozygous for each of the four mutations, 
respectively. These single-plex reactions were performed each time a batch of samples 
were screened for the four mutations using the multiplex assay and were used as positive 
controls. When repeated attempts on a sample failed to show all four mutation results, 
due to less amplification of a certain exon, subsequent single-plex SNaPshot reactions 
were used. Single-plex SNaPshot PCR was also conducted in a 10μl reaction volume, 
consisting of 1μl PCR product, 1μl single SNaPshot primers specific for mutation of 
interest (using a working stock of 10μM), and 1μl SNaPshot® Multiplex Ready 
Reaction Mix (Applied Biosystems, Warringon, UK). The remaining volume was made 
up by using SABAX dH2O (Adcock Ingram, Johannesburg, SA). 
 
The cycling conditions for both the multiplex and single-plex SNaPshot PCRs were as 
follows:  25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 30 
seconds. This was conducted on the PX2 Thermocycler (Thermohybaid, Middlesex, 
UK). Samples were stored at 4°C. 
 
2.4.2.3 Post-SNaPshot purification 
 
Following SNaPshot PCR reaction, the SNaPshot products were purified using SAP 
(Promega, Madison, USA). An amount of 1U of SAP (Promega, Madison, USA) was 
added to the entire SNaPshot reaction, in order to remove unincorporated ddNTPs. The 
post-SNaPshot purification procedure involved thermal cycling conditions at 37°C for 














was completed, the products were stored in the dark, in order to prevent a reduction in 
the amount of fluorescence of each product due to degradation. 
 
2.4.2.4 Analysis of SNaPshot results using capillary electrophoresis on the 
ABI 3100 Genetic Analyser 
 
Once the post-PCR purification was completed, the products were resolved on the ABI 
3100 Genetic Analyser (Applied Biosystems, California, USA). A volume of 0.5μl of 
purified SNaPshot product, together with 9μl of Hi-Di
TM
 Formamide (Applied 




 size standard 
(Applied Biosystems, Warrington, UK) was pipetted into a MicroAmp 96-well reaction 
plate (Applied Biosystems, Warrington, UK) (Appendix 2). The function of the Hi-Di
TM
 
Formamide (Applied Biosystems, Warrington, UK) is to maintain the SNaPshot 





standard (Applied Biosystems, Warrington, UK) is used to estimate the size of the 
alleles obtained from the SNaPshot reaction. The mixture consisting of the sample, Hi-
Di
TM





size standard (Applied Biosystems, Warrington, UK) in the reaction plate were 
denatured at 95 ºC for 5 min, and cooled on ice for a further 5 min. The reaction plate 
was loaded onto the ABI 3100 Genetic Analyser (Applied Biosystems, California, 
USA). The settings for data capture were as follows: the dye set used for the analysis 
was E5, the analysis method used was GeneScan-120 liz, and the run module was 
SNP36_POP4. The SNaPshot data were analysed using the Genemapper 3.0 Genescan 
Software (Applied Biosystems, California, USA).  
 
Although the expected internal primer sizes for the detection of the R602W, C1490Y, 
IVS38-10T>C and L2027F mutations was 32, 34, 37, and 41bp respectively, the 
analysed SNaPshot results were not visualised at those exact locations. Instead they were 














for these observed shifts could be due the specific ddNTP that was incorporated, as each 
of the four ddNTPs contained a different fluorescent dye. 
 
2.4.2.5 Trouble-shooting: incorporation of V256V  
 
Attempts were conducted to incorporate the detection of the V256V mutation into the 
multiplex SNaPshot reaction along with the C1490Y, R602W, L2027F, and IVS28-
10T>C mutations. Initially, a SNaPshot primer specific for the detection of the V256V 
mutation was designed to bind to the antisense strand of exon 6. The V256V mutation is 
a splice mutation caused by a G>T nucleotide. Although numerous optimisations were 
attempted, the SNaPshot results for both the multiplex and single-plex reactions for a 
sample known to be heterozygous for V256V produced oscillating black and green 
peaks, representative of a C and A allele, respectively (Fig. 2.4). When optimisation was 
attempted using a known wild type sample (no V256V mutation), oscillating black peaks 
were visible (results not shown). A SNaPshot primer specific for the detection of the 
V256V mutation was designed to bind to the sense strand of exon 6, but SNaPshot 
results for both the multiplex and single-plex reactions for a sample known to be 
heterozygous for V256V produced oscillating blue and red peaks, representative of a G 
and T allele, respectively (Fig. 2.5). When optimisation was attempted using a known 
wild type sample (no V256V mutation), oscillating blue peaks were visible (results not 
shown). Optimisation attempts included i) altering the annealing temperature used 
during the SNaPshot reaction, which was attempted by setting up a temperature gradient 
ii) using a different post-PCR purification procedure (Appendix 2), and iii) excluding a 
post-PCR purification procedure step, in order to determine whether or not this was 




























Fig. 2.4 An electropherogram of the results obtained for a si gle-plex SNaPshot 
reaction to detect the V256V mutation using a SNaPshot primer specific for the 
antisense strand of exon 6 in the ABCA4 gene.  
The product size in bp is shown on the x-axis. The level of fluorescence is shown on the y-axis. The 
expected SNaPshot size for the known heterozygous sample was 46bp with a single green and black peak. 













Fig. 2.5 An electropherogram of the results obtained for a single-plex SNaPshot 
reaction to detect the V256V mutation using a SNaPshot primer specific for the 
sense strand of exon 6 in the ABCA4 gene.  
The product size in bp is shown on the x-axis. The level of fluorescence is shown on the y-axis. The 
expected SNaPshot size for the known heterozygous sample was 50bp, with a single blue and red peak. 
However, the results revealed oscillating blue and red peaks, across the region between 34bp and 51bp 
instead. 





































Incorporation of a fifth SNaPshot primer for the detection of the V256V proved 
unsuccessful. SNaPshot primers designed to bind to both the sense and antisense strand 
did not yield the desired specificity for V256V mutation detection. After numerous 
attempts, the V256V mutation was optimised to be detected using mutation detection by 
dHPLC analysis. 
 
2.4.3 Allele-specific PCR 
 
AS-PCR is used to differentiate between a wild type and mutant allele. The technique is 
based on the 3’ positioning of a nucleotide in one primer sequence that is 
complementary to the wild type allele, and the 3’ positioning of a nucleotide in the other 
primer sequence that is complementary to the mutant allele. In theory, only the primer 
consisting of the correctly matched 3’ nucleotide should bind to the appropriate allele 
and extend (Latorra et al. 2003b). DNA Taq polymerase does not have 3’ to 5’ 
exonuclease activity, and 3’ end mismatched nucleotides are extended less often than 
that of matched 3’ end nucleotides (Kwok et al. 1994).  
 
As mentioned in section 2.3.5, three primers are required for an AS-PCR, an external 
primer, a mutation-specific primer and a wild type-specific primer. The mutation-
specific and wild-type primers bind to one strand, and the external primer binds to the 
opposite strand.  
 
General AS-PCR was used to detect for the G863A mutation, using size-based 
separation, due to the addition of random nucleotide tails at the 5’ end of the wild type 
and mutation-specific primer sequences. The difference in size between the wild type- 
and mutation-specific PCR products was 10bp. For this reason, screening for the G863A 
mutation was detected using non-denaturing size-based separation conditions on the 
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General AS-PCR was attempted to detect the R152X mutation, with an expected PCR 
product of 84bp for a wild type allele, and 105bp for an allele containing the R152X 
mutation. This technique, however, was found to result in non-specific binding of the 
mutation-specific primer, resulting in the formation of two PCR products for samples 
known to be wild type, the amplification of which should therefore only produce a single 
band (Fig.2.6). As mentioned previously, allele-specific primers can be designed by 
placing a LNA residue on the 3’ end of the primer. The replacement of a normal 3’ end 
DNA nucleotide with a LNA residue at the mutation site has been shown to improve the 
discrimination between wild type and mutant alleles (Latorra et al. 2003b; Mouritzen et 
al. 2003). An AS-PCR using a 3’ LNA nucleotide in the sequences for both the wild 
type and mutation-specific primers was thus attempted. Optimisation procedures for the 











Fig. 2.6 An inverted digital photograph of a 1.5% agarose gel showing the products 
of from an AS-PCR to specifically detect the R152X mutation in exon 5, visualised 
with EtBr.  
Lane M represents the GeneRuler™ 100bp Plus DNA ladder (Fermentas Life Sciences, Hanover, USA), 
Lanes 1, 3, and 4 represent AS-PCR results from known heterozygous samples for the R152X mutation, 
whereas Lanes 2 and 5 represent AS-PCR results from known wild type samples that do not contain an 
R152X mutation. A slight non-specific mutant allele at 105bp was visualised in both wild type samples in 



















2.4.4. Denaturing high performance liquid chromatography 
 
dHPLC was used to detect sequence differences between two alleles or chromosomes, in 
particular the presence or absence of some of the mutations of interest investigated in 
this study. This technique was performed using the WAVE® Nucleic Acid Fragment 
Analysis System (Transgenomic Inc, USA) and can detect single base pair substitutions, 
and small deletions and insertions (Xiao and Oefner 2001). 
 
The dHPLC technique involves the binding of DNA molecules to a DNASep
™
 column - 
which is known as the stationary phase - and the subsequent separation of the molecules 
from the column. DNA molecules separate from the column, due to increasing 
concentrations of an organic solvent, called acetonitrile. This is known as the mobile 
phase (Xiao and Oefner 2001).  
 
There are three modes in which the WAVE® system can operate, namely fully-
denaturing, partially-denaturing, and non-denaturing. Fully-denaturing conditions are 
used to estimate the size of single stranded DNA molecules, such as primers, and will 
not be discussed further as it did not fall into the scope of this project. Partially-
denaturing conditions are used for mutation detection and SNP discovery, with the basis 
of strand separation being dependent on i) the size of the fragment, ii) the nucleotide 
composition of the fragment, and  ii) the temperature(s) at which the fragment will 
optimally denature or melt. Non-denaturing conditions are used for the sizing of double-
stranded DNA molecules; strand separation is thus dependent on size but not sequence 
(WAVE® System Operator’s Guide). 
 
2.4.4.1 Mutation detection (partially-denaturing) 
 
Prior to using partially denaturing conditions for mutation detection, the sequence of the 
specific PCR product being investigated is analysed using WAVEMAKER® software. 














partially denature, thus resulting in the partial separation of the two DNA strands in the 
helical structure. This is known as the helical fraction. Ideally, it is optimal to melt the 
sequence at a helical fraction of between 70 and 90 percent. At the specified 
temperature, heteroduplex PCR products elute first, due to their lower affinity for the 
column as a result of the mis-match in their sequence (WAVE® System Operator’s 
Guide). Before the commencement of mutation detection, samples are heated to 95°C 
for 5 min, followed by slow cooling for approximately an hour to allow for the re-
annealing of the alleles. Samples that are heterozygous for a mutation have a ratio of 
one-to-one for wild type-to-mutant allele; therefore heating will result in a combination 
of homoduplexes and heteroduplexes. Samples that are wild type, containing no 
mutation, will consist of only homoduplexes. Samples that are homozygous for a 
mutation will show the same profile as a wild type sample, since both alleles consist of 
the same DNA sequence. Thus, samples showing a wild type profile need to be mixed 
with a known wild type control sample and heated and cooled again in order to reveal 
whether it is actually wild type or not (WAVE® System Operator’s Guide). This is 
known as the “WAVE mixing experiment”.  
 
Screening for the V256V and R152X mutations was conducted using mutation detection 
under partially-denaturing conditions. Since the positions of the mutations were known, 
temperatures specific to the exact position of the mutation were used to melt the PCR 
product. Various parameters were optimised for both the V256V and R152X mutation 
detection methods in order to adequately visualise the profile difference between a 
sequence with and without the mutation. The optimised parameters included: i) the ideal 
temperature for discriminating between a sequence containing a mutation and a wild 
type sequence (temperature), ii) the rate at which the sample should be eluted from the 
column (flow rate), iii) the time period during which the sample should be eluted from 
the column (gradient duration), and iv) the amount of sample injected onto the column 


















Table 2.5 Optimised parameters for mutation detection using dHPLC for 
mutations V256V and R152X. 









Volume of PCR 
Product injected 
(µl) 
V256V 294 61.6 1.5 3 5 
R152X 230 56.5 1.5 2 5 
 
A wild type control and mutation positive control sample (heterozygous for the 
mutation) were included for every batch of test samples that was run by mutation 
detection using dHPLC for comparison. 
 
The samples which showed altered profiles compared to the wild type control after 
mutation detection using dHPLC, were selected for sequence analysis. This is essential 
in order to confirm the presence of a mutation at the specific position rather than a SNP 
or mutation in the nearby vicinity.  
 
2.4.4.2 Size-based separation (non-denaturing) 
 
Generally, the WAVE® system is able to distinguish between fragments that differ by 
one percent of the size of the PCR product, for example, a PCR product of 200bp can be  
distinguished from a PCR product of 202bp (WAVE® System Operator’s Guide). PCR 
products that are smaller in size elute first in comparison to larger ones, which is a result 
of less phosphates being present in the smaller sized fragment. Detection of the G863A 
mutation was completed by AS-PCR. The PCR products obtained from the AS-PCR 
were visualised by size-based separation under non-denaturing conditions at 50°C. The 
primers designed for AS-PCR for G863A mutation detection contained a random 
nucleotide tail, which lead to a size difference of 10bp between the wild type and mutant 















A wild type control and mutation positive control sample (heterozygous for the 
mutation) were included for every batch of test samples that was run by size-based 
separation using dHPLC for comparison. 
 
2.4.5 Cycle sequencing 
 
Cycle sequencing was used to determine the sequence changes causing altered dHPLC 
chromatogram profiles, in order to determine whether or not a mutation was indeed 
present in a sample. 
 
Cycle sequencing was conducted directly on the products obtained from PCR. No 
purification of the products obtained from the PCR’s was required as no primer dimers 
or non-specific products were visible in the PCR product when they were 
electrophoresed on an agarose gel. 
 
Cycle sequencing was performed using the BigDye® terminator cycle sequencing kit 
version 3.1 (Applied Biosystems, California, USA). Sequencing was conducted in a 20μl 
reaction volume using 3-5μl PCR product, 2μl termination mix (Applied Biosystems, 
California, USA), 4μl BigDye termination buffer (Applied Biosystems, California, 
USA), and 20pmol of the external primer (sense or antisense). The sense primer was 
used for the V256V mutation detection, whilst the antisense primer was used for the 
R152X mutation detection. 
 
The sequencing thermal cycling conditions included an initial denaturation step at 96°C 
for 5 min, followed by 30 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 60°C 
for 4 min. The protocol for the purification of the products following cycle sequencing is 















Sequencing resolution on the ABI 3100 Genetic Analyser (Applied Biosystems, 
California, USA) involved loading 5µl purified sequencing product, together with 8µl 
Hi-Di
TM
 Formamide (Applied Biosystems, Warrington, UK) into a 96-well reaction 
plate. The reaction plate was loaded onto the ABI 3100 Genetic Analyser (Applied 
Biosystems, California, USA). The settings for data capture were as follows: the dye set 
used for the analysis was Z, the analysis method used was BC-
3100POP4UR_seqOffFtOff.saz, and the run module was ultraseq36_POP4 def. Analysis 
was conducted using the ABI Prism™ DNA Sequencing Analysis Software. 
 
2.5 Family co-segregation analysis 
 
Following screening of the patient cohort for the seven common mutations, family 
studies were conducted (wherever possible, depending on the availability of samples) for 
the patients in whom two ABCA4 mutations were found. Only the two mutations 
identified in the affected probands were screened for in specific family members for 
whom a DNA sample was available. Where one or two mutations were identified in the 
affected individual using the multiplex SNaPshot assay, single-plex SNaPshot reactions 
were performed in the family studies for the specific mutation(s) detected. DNA samples 
from a patient’s family (usually from the mother, father, or siblings) are collected to 
screen for the patient’s mutations, once they have been identified in order to determine 
whether or not: (i) the mutations were co-segregating with disease within the family and 
(ii) the two mutations were transmitted in cis/trans. If an ABCA4 allele was found to 
carry more than one mutation (i.e. in cis) it was designated as a complex allele and not 
classified as disease-causing on its own. The 86 individuals, for whom two disease-
causing mutations were identified with the ABCR400 microarray, had been verified and 


















A significant aspect of the current study involved attempting to determine whether there 
was any genotype-phenotype correlation in individuals found to carry two disease- 
associated ABCA4 mutations. In this regard, an attempt was made to assess the 
pathogenicity of each of the seven ABCA4 mutations in this study using several 
bioinformatic tools/resources. 
 
Amino acid substitutions resulting from missense mutations (i.e. C1490Y, R602W, 
L2027F, and G863A) were investigated using four bioinformatic tools: a polymorphism 
phenotyping programme, PolyPhen (www.bork.embl-hiedelberg.de/PolyPhen); Sorting 
Intolerant From Tolerant (SIFT) (www.blocks.fhcrc.org/sift/SIFT.html); PANTHER 
PSEC (Thomas et al. 2003); and PMUT (http://mmb2.pcb.ub.es:8080/PMut/). Mutations 
thought to affect splicing were investigated using different programmes compared to 
missense mutations. The V256V mutation, which is located in exon 6, was investigated 
using the programme ESEfinder (http://exon.cshl.edu/ESE/), which is specific for exonic 
mutations. The IVS38-10T>C mutation, which is located in intron 38, was investigated 
using the Berkeley Drosophila Genome Project (BDGP) Splice Site Prediction 
programme (http://www.fruitfly.org/seq_tools/splice.html). 
 
2.6.1 A polymorphism phenotyping programme, PolyPhen 
 
The required input data for the PolyPhen (www.bork.embl-hiedelberg.de/PolyPhen) 
server is the amino acid sequence of the protein in conjunction with the position of the 
mutation in the sequence and the two amino acid variants involved (Ramensky et al. 
2002). PolyPhen uses homologues of the input amino acid sequence via a blast search to 
determine whether the amino acid replacement is compatible with the range of 
substitutions that have been previously observed at that particular position. Reference 














software to calculate the “profile matrix”. The index is measured by the position-specific 
independent counts (PSIC). Profile scores of the matrix represent logarithmic ratios of 
the likelihood that an amino acid will occur at a specific site to the likelihood that this 
same amino acid will occur at any other site in the peptide sequence. PolyPhen 
calculates the value of the difference between the profile scores of both variants 
occurring at the polymorphic position. The output reveals the proportion of sequences 
that were aligned to the query protein at the specific position, which could be used to 
determine the reliability of the resulting profile score (Ramensky et al. 2002). 
 
2.6.2 Sorting intolerant from tolerant (SIFT)  
 
SIFT (www.blocks.fhcrc.org/sift/SIFT.html) predicts whether an amino acid change will 
alter protein function, based on both the position and type of the change (Ng and 
Henikoff 2003). This programme presumes that amino acids that are conserved within 
protein families are important; therefore if a change is detected at a well-conserved 
position it tends to be predicted as being damaging to the protein. This presumption also 
pertains to amino acid changes from, for example, a polar amino acid to a hydrophobic 
one. The programme uses the query protein sequence to choose homologous proteins, 
creating an alignment of these proteins together with the query protein. By making use 
of the amino acids that appear at each site in the sequence, SIFT calculates the 
probability of an amino acid replacement being tolerated, and this is determined in part 
by the most frequent amino acid governing the specific site. SIFT provides predictions 
for amino acid substitutions at every position in the sequence for all 20 amino acids. 
Conservation values for amino acids at certain positions in the protein vary from log220 
(which equals a value of 4.32), when only one amino acid is seen at a specific position, 
to zero, when all possible amino acids are seen at a specific position. SIFT uses a 
median conservation value of 3.0. The median conservation value is an indication of the 
confidence of the prediction given for a certain amino acid substitution. The predictions 
of the function of an amino acid alteration on a protein with a higher median 
conservation score are less varied and therefore resulting in a greater false positive error. 














predicted to be tolerated. An amino acid substitution is predicted as being harmful to the 
protein if the value is less than 0.05 (Ng and Henikoff 2003).  
 
2.6.3 PANTHER PSEC 
 
PANTHER PSEC is a programme that uses a collection of protein families and 
subfamilies to determine whether or not a specific amino acid can occur at a particular 
position in protein families that are evolutionarily related amongst various species. This 
programme is very similar to SIFT, however, PANTHER PSEC utilises a different 
model or algorithm. The likelihood that a specific variant will alter protein function is 
determined by the substitution position-specific evolutionary conservation (sub-PSEC) 
score. The sub-PSEC score is obtained from the likelihood of observing different amino 
acids using a PANTHER hidden Markov model (HMM). The HMM profile has a 
different amino acid change at each site in the profile, which is based on the array of 
amino acids observed in an alignment of multiple homologous sequences (Thomas et al. 
2003; Thomas and Kejariwal 2004; Brunham et al. 2005). 
   
2.6.4 PMUT 
 
The PMUT (http://mmb2.pcb.ub.es:8080/PMut/) software functions at two levels: i) it 
gathers information from a local database containing mutation hotspots, and ii) it 
examines a query SNP in a particular protein. The input data required by PMUT is a 
protein sequence together with the position of the DNA variant. It can be specified to 
either analyse only one variant or to conduct a complete scan of all the possible variants 
that are found at the specific position. PMUT uses two neural networks that serve as 
predictor engines for mutational data (Ferrer-Costa et al. 2005). PMUT data outputs 
consist of: 
 a pathogenicity index that ranges zero to one. Mutations are noted as 














 a confidence index that ranges from zero to nine. A value of zero is seen as 
low, whilst a value of 9 is seen as high. 
 
2.6.5 Splicing mutations occurring in exonic regions  
 
Mutations occurring in the exons of the ABCA4 gene that appear to have an effect on 
splicing were investigated using a programme called ESEfinder 
(http://exon.cshl.edu/ESE/). This web-based programme scans for presumed exonic 
splicing enhancers (ESEs) in the given query sequence. Matrices which correspond to 
the motifs of four different Ser/Arg-rich (SR) proteins are used in this programme. SR 
proteins are composed of a family of splicing factors that are conserved and play various 
roles in the splicing pathway. ESEs act as binding sites for SR proteins. The human SR 
proteins are SF2/ASF, SC35, SRp40 and SRp55. The input data required for ESEfinder 
is the query nucleotide sequence. The output is given as a series of scores that have been 
designed in increments of one nucleotide. A score is considered to be a high value if it is 
larger than the threshold value set at the input stage. The default threshold values are as 
follows: SF2/ASF = 1.956, SC35 = 2.383, SRp40 = 2.670 and SRp55 = 2.676. For 
interpretation enhancement and standardisation, the results are displayed graphically, 
with the query sequence on the x-axis. Colour-coded bars represent the presence of a 
motif with a high score. The higher the motif score, the higher the bar. The width of the 
bar indicates the length and positioning of the motif (Cartegni et al. 2003). 
 
2.6.6 Splicing mutations occurring in intronic regions  
 
Mutations occurring in the introns of the ABCA4 gene that appear to have an effect on 
splicing were investigated using a programme called the BDGP Splice Site Prediction 
programme (http://www.fruitfly.org/cgi-bin/seq_tools/splice.pl). The programme uses a 
neural network to screen for both 5’ and 3’ splice sites. Subsequently, intronic mutations 
in the ABCA4 gene that didn’t appear to alter splicing were investigated further by 














perfomed by using the University of California Santa Cruz (UCSC) Genome browser 
(http://genome.ucsc.edu/index.html?org=Human&db=hg19&hgsid=154378218). This 
browser compares the input sequence to the genomes of different species. In order to 
determine whether or not the nucleotide was conserved amongst species, the tool “Blat” 
was used to map a portion of the sequence containing the mutation site to the specified 
Human genome (Human Mar. 2006, NCBI36/hg18, Assembly). 
 
2.7 Statistical analysis  
 
An attempt was made to correlate genotype status of the seven common ABCA4 
mutations with the phenotype of the subjects affected with an AAR. Statistical analysis, 
using the programme StatSoft Statistica (Release 9), was conducted in order to 
investigate this genotype-phenotype correlation. The analysis was performed using the 
genotyping results obtained from the mutation screening of the seven ABCA4 mutations 
conducted in the current study as well as the results obtained from the ABCR400 
microarray chip screening (collectively referred to as the total patient cohort). The 
combined results were analysed against phenotype data available for each patient. The 
clinical data available for the majority of the individuals was the AOO of the disease. 
AOO is the difference in years between birth date and the self-reported start of AAR 
symptoms (for example poor visual acuity and/or blurred vision and/or night blindness). 
Only patients who were identified to carry two of the seven mutations and who had a 
self-reported AOO were used in this analysis. 
 
Non-parametric analysis using the Kruskal-Wallis test was conducted to analyse the 
data. Non-parametric tests may be used as an alternative to parametric tests when the 
assumption of normality is violated and therefore the data does not cluster around a 
mean or expected value. A histogram depicts whether the data is normally distributed. 
Normally distributed data are represented by a symmetrical, bell-shaped curve, whereas 
data that is not normally distributed is asymmetrical showing skewing to either the left 














normal distribution and showed that the age distribution of the cohort was significantly 
different to what was expected, with a significant p-value of less than 0.01 (Fig. 2.7). 
This could be due to the fact that only a few individuals were identified with high AOO, 
since the AOO of an AAR is generally within the first two decades of life.  
 
Fig. 2.7. A histogram showing the non-normal age distribution of the patient 
cohort. 
 
The Kruskal-Wallis test can be used to test whether differences exist between the 
collection of paired mutation combinations of ABCA4 variations. In order for the 
sampling distribution of the test statistic to be well-approximated by the chi-squared 
distribution, sample sizes per paired combination of disease-causing variations in 
ABCA4 greater than or equal to five were included (Keller and Warrack 2000). AOO 














various paired mutation combinations that the patients were found to carry (genotypes) 
were used as the independent variable (plotted on the x-axis in Fig. 2.7). Individuals 
with the same combination of two of the seven ABCA4 mutations were grouped together 
and analysed against AOO.  
 
The proposed null hypothesis (HO) for the Kruskal-Wallis test was that in a South 
African cohort with a recessive AAR there is no significant difference between the 
median AOO for all paired mutation combinations in ABCA4. The proposed alternative 
hypothesis (HA) was that in a South African cohort with a recessive AAR a significant 
difference between the median AOO exists between at least one pair of paired mutation 
combinations in ABCA4.  
 
In order to reject the HO, a p-value of 0.05 was used. In the case of this analysis a p-
value of less than 0.05 would mean that the HO would be rejected, and that HA is 
assumed true (Keller and Warrack 2000). The Kruskal-Wallis test can only be used to 
determine whether a difference between the collection of paired mutation combinations 
of ABCA4 variations (genotypes) exists. Therefore, if the Kruskal-Wallis test does 
produce a significant p-value, a subsequent set of tests need to be performed in order to 
determine exactly which pairs differ with respect to median AOO.  
 
The Wilcoxon Rank Sum test for independent samples was used to conduct a pairwise 
comparison between the various paired mutation combinations (genotypes) against one 
another, in order to determine if there was a significant difference between each of the 
paired mutation combinations. Like the Kruskal Wallis testing, this test is conducted on 
non-normally distributed data, and is thus also a type of nonparametric test (Samuels and 
Witmer 1999; Keller and Warrack 2000). 
 
The proposed null hypothesis (HO) for the Wilcoxon Rank Sum test was that in a South 
African cohort with a recessive AAR there is no significant difference between the 
median AOO for the paired mutation combination A in ABCA4 compared to the paired 














in a South African cohort with a recessive AAR there is a significant difference between 
the median AOO of one paired mutation combination A in ABCA4 compared to the 
paired mutation combination B in ABCA4. These test were conducted and compared all 
possible paired mutation combinations in ABCA4. Variation A represents one paired 
mutation combination and variation B represents a different paired mutation 
combination.  
 
In the Wilcoxon Rank Sum test, paired mutation combinations in ABCA4 consisting of 
three or more individuals were included in the analysis. This was conducted in order to 
determine if paired mutation combinations in ABCA4 held any significance. To account 
for the amount of statistical comparisons performed on the data, adjustments for multiple 
tests needed to be conducted. This was performed using the Bonferroni correction, 
where the p-value of each pairwise comparison was adjusted for the total number of tests 































Chapter 3: Results 
 
3.1 Detection of the seven ABCA4 mutations 
 
 
Detection of C1490Y (exon 30), R602W (exon 13), L2027F (exon 44), and IVS38-
10T>C (exon 39) mutations were successfully incorporated into a multiplex SNaPshot 
reaction. The V256V (exon 6) and R152X (exon 5) mutations were detected by 
partially-denaturing conditions using dHPLC analysis. The G863A mutation (exon 17) 
was screened for using AS-PCR, and visualised by size-based separation using dHPLC 
analysis.  
 
Molecular testing for mutations in the ABCA4 gene was conducted on 1) the test cohort 
of 72 patients affected with an AAR, and 2) a control cohort of 269 individuals (100 
Caucasians and 169 specifically self-identified Afrikaners). Both cohorts were screened 
for the seven disease-causing ABCA4 mutations (i.e. C1490Y, R602W, L2027F, IVS38-
10T>C, V256V, G863A, and R152X). A summary of the results obtained from the 
patient and control screening is shown at the end of this section in Table 3.1. 
  
3.1.1 C1490Y mutation detection 
 
A sample was designated as heterozygous C1490Y by the presence of both a C and T 
allele, which were represented on the electropherogram by a black and red peak, 
respectively (Fig. 3.1). A sample was designated as homozygous C1490Y by the 
presence of a T allele, which was represented on the electropherogram by a red peak (no 
example shown). A sample was designated as wild type (i.e. not carrying a C1490Y 
mutation) by the presence of a C allele, which was represented on the electropherogram 















The C1490Y mutation was detected in the heterozygous state in 12/72 patient samples 
(16.67%) i.e. 12/144 alleles (8.33%). Homozygous C1490Y alleles were also detected in 
2/72 individuals (2.77%) in the patient cohort, i.e. 4/144 alleles (2.77%).  
 
The C1490Y mutation was detected in the heterozygous state in 2/269 (0.74%) 
individuals in the control cohort, i.e. 2/538 alleles (0.37%). The two heterozygotes 
(1.18%) were detected in the Afrikaner sub-cohort. This variant was only observed in 
the heterozygous state in the control cohort. 
 
3.1.2 R602W mutation detection 
 
A sample was designated as heterozygous R602W by the presence of both a G and A 
allele, which were represented on the electropherogram by a blue and green peak, 
respectively (Fig. 3.1). A sample was designated as homozygous R602W by the 
presence of an A allele, which was represented on the electropherogram by a green peak 
(no example shown). A sample was designated as wild type (i.e. not carrying a R602W 
mutation) by the presence of a G allele, which was represented on the electropherogram 
by a blue peak (Fig. 3.2 and 3.3).   
 
The R602W mutation was detected in the heterozygous state in 10/72 patient samples 
(13.88%), i.e. 10/144 alleles (6.94%). This variant was only observed in the 
heterozygous state in the patient cohort. 
 
The R602W mutation was detected in 2/269 individuals (0.74%) in the control cohort, 
i.e. 2/538 alleles (0.37%). The two heterozygotes (1.18%) were detected in the Afrikaner 



























Fig. 3.1 An electropherogram of the multiplex SNaPshot reaction, showing the 
results obtained for a sample that is heterozygous for both the R602W and C1490Y 
mutations. 
The R602W alleles are indicated by blue and green peaks at 36bp and 37 bp, respectively. The C1490Y 
alleles are indicated by black and red peaks at 38bp and 39bp, respectively. The IVS38-10T>C wild type 
allele is represented by a red peak at 41.5bp. The L2027F wild type allele is represented by a blue peak at 
45bp. The LIZ Size Standard can be seen at 35bp. 
 
3.1.3 L2027F mutation detection 
 
A sample was designated as heterozygous L2027F by the presence of both a G and A 
allele, which were represented on the electropherogram by a blue and green peak, 
respectively (Fig. 3.2). A sample was designated as homozygous L2027F by the 
presence of an A allele, which was represented on the electropherogram by a green peak 
(no example shown). A sample was designated as wild type (i.e. not carrying a L2027F 
mutation) by the presence of a G allele, which was represented on the electropherogram 
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The L2027F mutation was detected in the heterozygous state in 12/72 patient samples 
(16.67%), i.e. 12/144 alleles (8.33%). This variant was only observed in a heterozygous 
state in the patient cohort. 
 
The L2027F mutation was detected in the heterozygous state in 2/269 individuals 
(0.74%) in the control cohort, i.e. 2/538 alleles (0.37%). One heterozygote (0.59%) was 
detected in the Afrikaner sub-cohort and the other (1%) the Caucasian sub-cohort. This 













Fig. 3.2 An electropherogram of the multiplex SNaPshot reaction, showing the 
results obtained for a sample that is heterozygous for the L2027F mutation. 
The R602W wild type allele is indicated by a blue peak at 36bp. The C1490Y wild type allele is indicated 
by a black peak at 38bp. The IVS38-10T>C wild type allele is represented by a red peak at 41.5bp. The 
L2027F alleles are represented by blue and green peaks at 45bp and 46bp, respectively. The LIZ Size 
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Fig. 3.3 An electropherogram of the multiplex SNaPshot reaction, showing the 
results obtained for a sample that is heterozygous for the IVS38-10T>C mutation. 
The R602W wild type allele is indicated by a blue peak at 36bp. The C1490Y wild type allele is indicated 
by a black peak 38bp. The IVS38-10T>C alleles are represented by a black and red peak at 40bp and 
41.5bp, respectively. The L2027F wild type allele is represented by a blue peak at 45bp. The LIZ Size 
Standard can be seen at 35bp. 
 
3.1.4 IVS38-10T>C mutation detection 
 
A sample was designated as heterozygous IVS38-10T>C by the presence of both a C 
and T allele, which were represented on the electropherogram by a black and red peak, 
respectively (Fig. 3.3). A sample was designated as homozygous IVS38-10T>C by the 
presence of a C allele, which was represented on the electropherogram by a black peak 
(no example shown). A sample was designated as wild type (i.e. not carrying an IVS38-
10T>C mutation) by the presence of a T allele, which was represented on the 





















































The IVS38-10T>C mutation was detected in the heterozygous state in 9/72 patient 
samples (12.5%), i.e. 9/144 alleles (6.25%). The mutation was detected in a homozygous 
state in 2/72 (2.77%) patients, i.e. 4/144 alleles (2.77%). 
 
The IVS38-10T>C mutation was not observed in the control cohort of 269 individuals.  
 
3.1.5 V256V mutation detection 
 
After the “WAVE mixing experiment” (defined in section 2.4.4.1) was performed, 
mutation screening by dHPLC showed 11 patient samples to have the identical 
chromatogram profile to that of the positive control, while one sample was suspected to 
be homozygous V256V. Two control samples were found to have an identical 
chromatogram profile to that of the positive control. One control sample was of 
Caucasian ethnicity and the other was of Afrikaner descent. A different Afrikaner 
control sample (sample 2.13) was shown to have a different chromatogram profile to 








Fig. 3.4 A dHPLC chromatogram showing the heterozygous profile (Het V256V), 
wild type profile (Wild Type), and a unique profile (2.13) with an altered pattern 
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The 15 samples shown to have altered chromatogram profiles in comparison to the wild 
type control when exon 6 was screened by dHPLC, were sequenced in order to confirm 
the presence of the V256V mutation (Fig. 3.5). Cycle sequencing results for the 12 
patient samples confirmed the presence of 11 heterozygotes and one homozygote in the 
patient cohort. Cycle sequencing results furthermore confirmed the presence of a 
heterozygous V256V mutation in two control samples; however no V256V mutation (or 
any other sequence alteration) was present in exon 6 of sample 2.13. 
  
 
Fig. 3.5 Sequencing electropherograms showing the heterozygous c.768G>T 
(V256V) mutation (detected in 13 individuals), homozygous c.768G>T (V256V) 
mutation (detected in one individual) and the wild type sequence of sample 2.13, 
that had produced an aberrant dHPLC profile. 
 
In summary, a heterozygous V256V mutation was detected in 11/72 (15.28%) patients, 
i.e. 11/144 alleles (7.63%). Two V256V mutations (homozygotes) were also detected in 
1/72 patient samples (1.39%), i.e. 2/144 alleles (1.39%).  
 
A V256V mutation was detected in 2/269 (0.74%) samples in the control cohort, i.e. 
2/538 alleles (0.37%). One heterozygote was detected in each of the sub-cohorts of 
Caucasian (1%) and Afrikaner (0.59%) descent.  
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3.1.6 G863A mutation detection 
 
A sample was designated as heterozygous G863A by the presence of both a C and a G 
allele, producing a chromatogram profile containing 3 peaks (Fig. 3.6). A sample was 
designated as wild type, and therefore did not carry a G863A mutation, by the presence 
of a C allele, producing a chromatogram profile containing a single peak (Fig. 3.6).   
 
A heterozygous G863A mutation was detected in 7/72 patient samples (9.72%), i.e. 
7/144 alleles (4.86%). No patients were found to carry two G863A alleles in the 
homozygous state.  
 
A heterozygous G863A mutation was detected in 3/269 of the individuals (1.12%) in the 
control cohort, i.e. 3/538 alleles (0.56%). Two heterozygotes were detected in the 









Fig. 3.6 A dHPLC chromatogram showing the wild type profile and the profile 
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3.1.7 R152X mutation detection 
 
The R152X mutation in exon 5 could not be detected using an AS-PCR, even when a 
single LNA nucleotide was incorporated at the 3’ end of both the mutation-specific and 
wild type-specific primers. Screening for the R152X mutation in exon 5 was performed 
by partially-denaturing conditions using dHPLC analysis.  
 
After the “WAVE mixing experiment” was performed, mutation screening by dHPLC 
showed eight patient samples to have identical chromatogram profiles to that of the 
positive control. Three control samples were found to have an ide tical chromatogram 
profile to that of the positive control. All three control samples were of Afrikaner 









Fig. 3.7 A dHPLC chromatogram showing the wild type profile, and the profile 
obtained when a heterozygous R152X mutation is present. 
 
The 11 samples shown to have altered chromatogram profiles in comparison to the wild 
type control when exon 5 was screened by dHPLC, were sequenced in order to confirm 
the presence of the R152X mutation (Fig. 3.8). Cycle sequencing using the antisense 
primer revealed that the R152X mutation was not present in one of the patient samples 
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a single c.455G>A mutation (R152Q) which was found directly 3’ of the R152X 
mutation site (c.454C>T). Due to the fact that the R152Q mutation was situated in such 
close proximity to the R152X mutation site, it had resulted in the chromatogram profile 
of the three samples being identical to the dHPLC chromatogram profile of the positive 
control. Cycle sequencing results confirmed the presence of a heterozygous R152X 








Fig. 3.8 Sequencing electropherograms showing the wild type sequence, 
heterozygous c.454C>T (R152X) mutation, and the Afrikaner control sample 
(2/749) that was shown to carry a c.455G>A (R152Q) directly flanking the R152X 
mutation site.   
 
In summary, a R152X mutation was detected in 7/72 (9.72%) patient samples, i.e. 7/144 
alleles (4.86%). No patients were found to carry two R152X mutations in the 
homozygous state.  
 
A R152X mutation was detected in 1/269 (0.37%) individuals in the control cohort, i.e. 




















 Table 3.1 The results from screening both the patient and control cohort for seven 
ABCA4 mutations, showing the number and frequency of mutant alleles detected 
per mutation. 
The frequencies of the mutant alleles are shown in brackets. 
 
 In summary, 78/144 (54.17%) pathogenic alleles were detected in the 72 patients 
screened. Twenty-two (30.55%) patients were found to carry one mutation, 28 (38.89%) 
were found to carry two mutations, and 22 (30.55%) were shown not to carry any of the 
seven mutations. The majority of the patients found to carry two mutations were 
compound heterozygotes (n = 23 individuals) (82.14%), with the remaining five being 
identified as homozygotes (17.86%). A total of 16 different paired combinations of 
pathogenic variations in ABCA4 were detected in the 28 patients with two mutations. 
 
Of the 269 control samples screened, 12 (4.46%) were shown to carry a heterozygous 
mutation. Four heterozygotes (4%) were detected in the Caucasian sub-cohort, with 
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3.2 Familial co-segregation analysis 
 
Where possible, family studies were conducted in order to determine whether the two 
mutations identified in 28 patient samples (23 compound heterozygotes and five 
homozygotes) were co-segregating with the disease within the family, and whether these 
mutations existed “in trans” (i.e. were bi-allelic). Extended pedigrees and biological 
material from family members were available for 10 of the 28 individuals, and co-
segregation analysis could thus be conducted (Fig. 3.9 a to j). The results for each of the 
10 families are shown below:  
 
Family 107 (Fig. 3.9a): The affected individual, RPS 107.2TAB, was found to carry two 
C1490Y mutations (i.e. homozygous C1490Y). Familial co-segregation analysis showed 
that each parents carried a heterozygous C1490Y mutation. 
 
Family 125 (Fig. 3.9b): The affected individual, RPS 125.1TRB, was found to be a 
compound heterozygote, carrying both a C1490Y and R152X mutation. Familial co-
segregation analysis showed that the father (RPS 125.3SOR) carried a heterozygous 
R152X mutation, while the mother (RPS 125.2ELI) carried a heterozygous C1490Y 
mutation. 
 
Family 133 (Fig. 3.9c): The affected individual, RPS 133.4CHA, was found to carry 
two V256V mutations (i.e. homozygous V256V). Familial co-segregation analysis 
showed that each parent carried a heterozygous V256V mutation. The unaffected sister 
(RPS 133.3YOL) was shown not to carry any V256V mutation. 
 
Family 151 (Fig. 3.9d): The affected individual, RPS 151.3DAN, was found to be a 
compound heterozygote, carrying both a C1490Y and R602W mutation. Familial co-
segregation analysis showed that the father (RPS 151.1DJF) carried a heterozygous 














mutation. The unaffected brother (RPS 151.5DEW) was shown to carry a heterozygous 
C1490Y mutation (the maternal allele). The mutations carried by the affected younger 
brother (RPS 151.4FRE) could not be determined as no biological material was available 
for this individual.  
 
Family 114 (Fig. 3.9e): The affected individual, RPS 114.3BER, was found to be a 
compound heterozygote, carrying both a C1490Y and IVS38-10T>C mutation. Familial 
co-segregation analysis showed that the father (RPS 144.7STE) carried a heterozygous 
IVS38-10T>C mutation, while the mother (RPS 114.5THE) carried a heterozygous 
C1490Y mutation. The unaffected paternal uncle (RPS 114.1EUG) was also shown to 
carry a heterozygous IVS38-10T>C mutation. The unaffected maternal aunt (RPS 
114.2WAY) did not carry the C1490Y mutation. The unaffected sister (RPS 114.6NIC) 
was shown to carry a heterozygous C1490Y mutation (maternally inherited). The 
younger affected brother (RPS 114.4BAR) was also shown to be a compound 
heterozygote, carrying both a C1490Y and IVS38-10T>C mutation.  
 
Family 232 (Fig. 3.9f): The affected individual, RPS 232.1SUR, was found to be a 
compound heterozygote, carrying both a R152X and V256V mutation. Familial co-
segregation analysis showed that the father (RPS 232.2JOH) carried a heterozygous 
V256V mutation. No biological material was available for the mother of the affected 
individual, who, according to the pedigree had a retinal disease, but was deceased. 
However, since the father (RPS 232.2JOH) was shown to carry one V256V mutation, it 
could be inferred, that the R152X mutation was transmitted from the mother.  
 
Family 226 (Fig. 3.9g): The affected individual, RPS 226.1KOB, was found to be a 
compound heterozygote, carrying both a C1490Y and R152X mutation. Familial co-
segregation analysis showed that the father (RPS 226.4ALB) carried a heterozygous 
C1490Y mutation, while the mother (RPS 226.2PET) carried a heterozygous R152X 















Family 549 (Fig. 3.9h): The affected individual, RPS 549.1ZAN, was found to be a 
compound heterozygote, carrying both a V256V and L2027F mutation. Familial co-
segregation analysis showed that the father (RPS 549.2PHI) carried a heterozygous 
L2027F mutation. No biological material was available for the mother. However, since 
the father (RPS 549.2PHI) was shown to carry one L2027F mutation, it is most likely 
that the V256V mutation was inherited from the mother.  
 
Family 464 (Fig. 3.9i): The affected individual, RPS 464.1SAN, was found to be 
compound heterozygous, carrying both a R602W and G863A mutation. Familial co-
segregation analysis showed that her unaffected offspring (RPS 464.2STE and RPS 
464.3NEI) each carried a heterozygous R602W mutation. The offspring were not shown 
to carry the heterozygous G863A mutation. The disease status of the affected 
individual’s husband was unknown, and no biological material was available for this 
individual.  
 
Family 352 (Fig. 3.9j): The affected individual, RPS 352.1DEO, was found to be a 
compound heterozygote, carrying both a R152X and L2027F mutation. This patient was 
married to RPS 352.2ARL who was also shown to be affected with a retinal disease. 
Although the clinical details for the proband indicated that he was affected with STGD 
disease, the exact retinal disease of his spouse was not known. The two disease-causing 
mutations detected in the proband were not detected in his spouse. Interpretation for this 
result could be that the spouse carries two other ABCA4 mutations (if she is affected 


























































a) Family 107 b)  Family 125 
c)  Family 133 d)  Family 151 
e)  Family 114 
C1490Y        0/1 C1490Y        0/1 
C1490Y        1/1 
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R152X            0/1 
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R152X            0/0 
C1490Y         0/1 
R152X            0/1 
AOO 
8 years 
V256V         0/1 V256V         0/1 
V256V         0/0 V256V         1/1 
AOO 
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C1490Y               0/0 
IVS38-10T>C     0/1 
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IVS38-10T>C     0/1 
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IVS38-10T>C     0/0 
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C1490Y               0/1 
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C1490Y               0/1 
IVS38-10T>C     0/1 
C1490Y               0/1 
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C1490Y       0/1 
R602W         0/0 
C1490Y       0/1 
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C1490Y       0/1 









































Fig. 3.9 The 10 family pedigrees available for co-segregation analysis.  
The square represents a male and a circle represents a female. Shaded symbols indicate an affected 
individual and a symbol that has a line through it indicates that individual is deceased. AOO indicates the 
age of onset of the disease. An individual given the number 0/0 next to the appropriate mutation name 
indicates the individual is wild type and therefore does not carry that mutation. An individual given the 
number 0/1 next to the appropriate mutation name indicates the individual is heterozygous for the 
mutation, carrying only one allele with that mutation. An individual given the number 1/1 next to the 
appropriate mutation name indicates the individual is homozygous and therefore carries two alleles with 
that mutation. 
f)  Family 232 g)  Family 226 
h)  Family 549 i)  Family 464 
j)  Family 352 
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3.3.1 Missense Mutations 
 
In order to assess the pathogenicity of each of the four missense ABCA4 mutations 
(C1490Y, R602W, G863A, and L2027F) investigated in this study, several 
bioinformatics programmes were utilised, namely PolyPhen; SIFT; PANTHER PSEC; 
and PMUT (Table 3.2). 
 
Of the four missense mutations, the C1490Y mutation was predicted to have the highest 
pathogenic score in three out of the four software packages used. Although SIFT 
revealed R602W to have a slightly higher median conservation score in comparison to 
the G863A mutation (i.e. nucleotide change is less diverse and therefore has a higher 
false positive rate), this mutation was predicted as the second most pathogenic. The 
G863A mutation was ranked as the third most pathogenic overall. The L2027F mutation 
was assigned a lower subPSEC score in comparison to the G863A mutation using 
PANTHER PSEC, suggesting it to be more deleterious. However, when L2027F was 
investigated using the other three bioinformatics programmes (PolyPhen, SIFT, and 























Table 3.2 The bioinformatic results obtained using PolyPhen, PMut, Panther 
PSEC, and SIFT for the four ABCA4 missense mutations C1490Y, R602W, 
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PSIC score difference: 
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3.3.2 Splicing mutations occurring in exonic regions 
 
The web-based programme, ESEfinder, predicted a change in the splicing profile of the 
wild type sequence in comparison to the sequence containing the V256V mutation. 
Analysis of both sequences revealed the binding of an additional SR protein, SRp40, in 
the mutant V256V sequence (Fig. 3.10). The binding of SRp40 to this sequence, is the 
result of the generation of another ESE motif in the sequence, created by the V256V 
mutation. As mentioned previously, SR proteins play various roles in the splicing 
pathway of a nucleotide sequence. By creating a binding site for an additional SR 














Fig. 3.10 Graph showing the results from ESEfinder analysis for the V256V 
mutation.  
The top graph shows the results obtained for the wild type sequence, with the bottom graph showing the 
results from the sequence containing the V256V mutation. An additional SRp40 protein was found to bind 
to the sequence when the V256V mutation was present. This is shown by the additional green motif that is 

















3.3.3 Splicing mutations occurring in intronic regions 
 
 The BDGP Splice Site Prediction programme did not predict any significant alteration 
to the donor or acceptor splice site when the wild type sequence of exon 39 (including 
part of intron 38) was compared to the sequence containing the IVS38-10T>C mutant 
allele. This result was not expected since the IVS38-10T>C mutation is situated in the 5’ 
splice acceptor site, 10bp away from the intron-exon boundary of exon 39. Investigation 
into the conservation of the wild type nucleotide amongst species, using the UCSC 
Genome browser, showed that the nucleotide was highly conserved (Fig. 3.11). 
Conservation of the wild type nucleotide amongst species could imply its importance in 
the correct functioning of the ABCA4 gene. 
 
Fig. 3.11 The results obtained from the UCSC Genome browser showing the 
conservation of the wild type nucleotide at position 10bp 5’ of exon 39.  
The green rectangle highlights the conservation of the nucleotide amongst the different species. 
 
IVS38-10T>C is listed as a mutation on the ABCR400 microarray chip (M Mällo, 














10T>C as a pathogenic mutation. For the purpose of this study, IVS38-10T>C was thus 
regarded as a disease-causing variant. 
 
3.3.4 Rating the pathogenicity of the seven common ABCA4 mutations  
 
Both bioinformatic tools as well as extensive literature research were utilised in order to 
assess the pathogenicity of all seven ABCA4 mutations. Of the seven mutations four 
were missense mutations, one resulted in a stop codon, whilst the remaining two were 
expected to affect splicing. 
 
Previous investigations assessing the functions of the missense mutations C1490Y and 
R602W, revealed a decrease in the amount of hydrolytic activity in both the mutant 
alleles compared to that of the wild type allele (Wisniewsk et al. 2005). It was also noted 
that the presence of either of these two missense mutations resulted in the expression of 
the ABCA4 protein in the inner segment of rod cells and not in the original site of the 
outer segment. These variants have therefore been designated as mislocalisation alleles. 
According to Wisniewsk et al. (2005), these two mutations appear to have a dual effect 
on the ABCA4 protein, affecting both the function and the end localisation of the 
protein. The results obtained from the bioinformatic analysis predicted the C1490Y and 
R602W mutations to be the most pathogenic. Therefore, C1490Y and R602W were 
ranked as the first and second most pathogenic of the seven mutations, respectively. 
 
The V256V mutation does not result in an altered amino acid residue. The nucleotide 
substitution (c.768G>T) has, however, been shown to create an alternative splice site, 
which leads to an abnormal ABCA4 transcript (Valverde et al. 2006). The result 
obtained using the bioinformatic tool, ESEfinder, also indicated a possible role for 
V256V in alternative splicing, with the prediction of an additional ESE binding site for 
an SR protein, SRp40, when the mutation is present. Investigations into the functional 














(Klevering et al. 2004). This mutation was thus rated as the third most pathogenic 
mutation.  
 
The R152X mutation occurs as a result of a nucleotide substitution (c.454C>T), and 
leads to a premature stop codon in exon 5, thus resulting in a truncated protein. When 
the R152X mutation is present in the heterozygous state, it causes the inactivation of the 
ABCA4 allele (Zhang et al. 1999). Unlike the C1490Y and R602W mutations, which 
result in mislocalisation of the ABCA4 protein, and the V256V mutation, which appears 
to be involved in alternative splicing, and could be more hazardous to the retina; R152X 
results in a non-functional allele, leading to a large decrease in total ABCA4 protein 
activity. This mutation has thus been designated as the fourth most pathogenic mutation 
of those screened for in the present study.  
 
Previous investigations into the function of the missense mutation (c.2588G>C) 
resulting in the G863A amino acid change, have shown that this mutation has a mild 
effect on ABCA4 protein activity in individuals affected with STGD disease and is 
associated with a later AOO (Maugeri et al. 1999; Shroyer et al. 2001). Bioinformatic 
analysis of the mutation predicted it to be less pathogenic in comparison to the C1490Y 
and R60W mutations. The G863A mutation was designated as the fifth most pathogenic 
ABCA4 mutation. 
 
The missense mutation, c.6079C>T, results in a L2027F amino acid change. This 
mutation is located in the NBD2 and research has shown it has an effect on ABCA4 
protein expression and ATP binding (Sun et al. 2000). In most cases bioinformatic 
analysis predicted L2027F to be less severe in comparison to the other three missense 
mutations, namely C1490Y, R602W, and G863A (listed in decreasing predicted 
pathogenicity according to the bioinformatic results obtained) and was therefore 
predicted as the least pathogenic of the four mutations. In the group of mutations as a 
whole, L2027F was designated as the sixth most pathogenic ABCA4 mutation of the 














Several researchers have investigated the function of the IVS38-10T>C mutation on 
ABCA4 protein function (Maugeri et al. 1999; Rivera et al. 2000; Klevering et al. 2004). 
Although situated in a splice acceptor site, this mutation is not predicted to alter splicing, 
however, other researchers still consider it pathogenic (M Mällo, personal 
communication; Klevering et al. 2005). This mutation was thus designated the least 
pathogenic of the seven ABCA4 mutations investigated in this study.  
 
3.4 Statistical analysis  
 
Non-parametric analysis was conducted in order to investigate the influence of the seven 
common ABCA4 mutations on the clinical phenotype of AAR-affected individuals. The 
analysis was performed using the results obtained from the mutation screening of the 
seven ABCA4 mutations in this project as well as the results obtained from the 
ABCR400 microarray chip screening. A total of 28 samples in the patient cohort of this 
project were found to carry two of the seven mutations. Results from previous 
microarray screening and family studies in our laboratory, identified a total of 86 
individuals from 66 families that were found to carry two of the seven mutations. This 
resulted in a total of 114 individuals who were found to carry two of the seven ABCA4 
mutations and a total of 23 different paired mutation combinations. Of the 114 
individuals, only patients for whom a self-reported AOO was available were used in this 
analysis. Data was available from a total of 106 patients from 94 families (26 of the 28 
patients in the current study, and 80 of the 86 patients screened by the ABCR400 
microarray chip) (Table 3.3).  
 
The AOO varied depending on the mutation combination. The four mutations predicted 
to be most highly pathogenic (C1490Y, R602W, V256V, and R152X) appeared to have 
a similar average AOO range of between six to 12 years. The C1490Y mutation in 
combination with either itself or another common mutation was detected in 56 of the 
106 patient samples. The IVS38-10T>C mutation was identified in a total of 23 patients 














with an exception being seen when it was found to occur in combination with G863A, 
resulting in a later AOO. In fact, when the G863A mutation was present in combination 
with one of the other common mutations, the AOO was later. No individuals were found 
to carry two G863A mutations. 
 
 Table 3. 3 A summary of the 23 mutation combinations observed in 106 patients 
with AARs, showing the number of patients per combination and the range and 
average of the AOO (in years) per combination. 
 
 
The Kruskal-Wallis test was performed where AOO was used as the dependent variable 












AOO (in years): 
Range; Average 
C1490Y + IVS38-10T>C 9 3 12 5-12; 8.9 
C1490Y + R602W 9 2 11 4-13; 8.1 
C1490Y + L2027F 10 - 10 7-18; 10.5 
C1490Y + V256V 9 1 10 7-12; 10.3 
C1490Y (HOMO) 6 2 8 7-9; 8.1 
R602W + L2027F 6 2 8 8-22; 12 
L2027F + R152X 5 1 6 6-11; 7.6 
C1490Y + R152X 3 2 5 7-9; 8 
L2027F + V256V 2 3 5 10-14; 12 
V256V + R152X 3 1 4 5-10; 8 
C1490Y + G863A 3 - 3 19-20; 19.3 
R602W + V256V 2 1 3  4-10; 6.7 
L2027F + IVS38-10T>C 2 1 3 7-16; 11 
IVS38-10T>C + R152X 3 - 3 5-8; 7 
G863A + R152X 3 - 3 30-36; 32 
V256V + G863A 1 2 3 12-20, 16.7 
R602W + G863A 1 1 2 8-27; 17.5 
IVS38-10T>C (HOMO) - 2 2 6-7; 6.5 
R602W + IVS38-10T>C 1 - 1 11;11 
IVS38-10T>C + G863A 1 - 1 20;20 
L2027F (HOMO) 1 - 1 28; 28 
V256V (HOMO) - 1 1 8; 8 














were used as the independent variable (plotted on the x-axis). Patients with the same 
mutation combination were grouped together and sample sizes less than five were 
excluded (Fig. 3.12). This resulted in a total of nine different mutation combinations 
being included in the analysis (n = 76 patients). 
 
The Kruskal-Wallis analysis revealed a p-value of 0.003. Since the p-value was less than 
0.05, the proposed null hypothesis (HO), stating that in a South African cohort with a 
recessive AAR there is no significant difference between the median AOO for all paired 
combinations of disease-causing variations in ABCA4, was rejected. The proposed 
alternative hypothesis (HA) stating that in a South African cohort with a recessive AAR a 
significant difference between the median AOO exists between at least one pair of 
disease-causing variations in ABCA4, was then assumed.  
 
Having established that there were differences in AOO between the different genotypes, 
the Wilkoxon Rank Sum test was used to determine exactly which genotype groups 
differ with respect to AOO. For one particular paired combination (G863A+R152X, n = 
3 individuals), a much later AOO (i.e. 30 years and older) was observed in comparison 
to the other mutation combinations. In order to test whether this observation held any 
significance, paired mutation combinations carried by three or more individuals were 
included for this analysis. This resulted in a total of 16 different mutation combinations 
being included in the analysis (n = 97 individuals). A total of 120 different pairwise 
comparisons (mutation combination A versus mutation combination B) were conducted 
and significant p-values were obtained for 37 different paired mutation combinations. 
Due to the large number of statistical comparisons being performed on the data, 
adjustments for the multiple pairwise comparisons was conducted. This was performed 
using the Bonferroni correction, where the p-value of each pairwise comparison was 
adjusted for the 120 tests. After Bonferroni corrections were made for the multiple 
comparisons, by multiplying each observed p-value obtained from the analysis by 120 
(the number of tests conducted), none of the 37 previously significant p-values remained 
















Fig. 3.12 A graph showing the results from the non-parametric Kruskal-Wallis test 
comparing AOO and nine genotype groups.  
AOO is represented on the y-axis. The various genotypes are shown on the x-axis: 1 - homozygous 
C1490Y genotype, 2 - Heterozygous C1490Y and R602W genotype, 3 - heterozygous C1490Y and 
V256V genotype, 4 - heterozygous C1490Y and R152X genotype, 5 - C1490Y and L2027F genotype, 6 - 
R602W and L2027F genotype, 7 - C1490Y and IVS38-10T>C genotype, 8 - L2027F and V256V 





































































































































































Chapter 4: Discussion 
 
Since ABCA4 was identified as the gene responsible for causing arSTGD, its 
involvement with this disease and other retinal diseases has been investigated 
extensively (Allikmets et al. 1997a; Cremers et al. 1998; Briggs et al. 2001; Klevering et 
al. 2005; Rosenberg et al. 2007). Historically, studies have focused on populations in 
Europe and research into AARs from emerging countries, including South Africa, has 
been lacking.  
 
September et al. (2004) investigated the spectrum of ABCA4 mutations involved with 
arSTGD and showed six common disease-associated sequence variants underlying 
arSTGD in that cohort. More than 90% of the cohort was of Afrikaner descent. The 
study formed part of a broader investigation to determine the genes underlying many 
different types of RDD in the South African population (September PhD thesis, 2003). 
 
Subsequently, material from a cohort of South Africans affected with an AAR, archived 
in the Division of Human Genetics at UCT, was screened for mutations in the ABCA4 
gene using the ABCR400 microarray chip, in order to assess the spectrum of mutations 
in the population. This screening detected a large number of causative mutations, with 
seven mutations found to be relatively common, namely C1490Y, R602W, IVS38-
10T>C, L2027F, V256V, G863A, and R152X. 
 
The aim of the current study was to investigate the founder effect of the seven most 
common ABCA4 mutations in South African individuals in order to determine the carrier 














4.1 Detection of the seven ABCA4 mutations 
 
Reproducible, sensitive assays were created in order to detect all seven ABCA4 
mutations. 
 
Detection of the C1490Y, R602W, IVS38-10T>C, and L2027F mutations was 
performed by designing a multiplex SNaPshot assay. The incorporation of an additional 
internal SNaPshot primer for the detection of the V256V mutation into the designed 
multiplex SNaPshot reaction was attempted, however, this proved problematic. Firstly, 
the internal SNaPshot primer was designed to bind to the antisense strand of the DNA 
sequence. Oscillating black and green peaks (corresponding to a C and A allele, 
respectively) were visualised during optimisation when using a heterozygous V256V 
mutation-positive control. Also, oscillating black peaks (corresponding to a C allele) 
were seen when a wild type control was tested. Instead of the expected SNaPshot 
product size of around 46bp, the oscillating peaks were observed across the region 
between 34bp and 49bp. Secondly, an internal SNaPshot primer was designed to bind to 
the sense strand of the DNA sequence, however, this produced similar results. 
Oscillating blue and red peaks (corresponding to a G and T allele, respectively) were 
visualised during optimisation using a heterozygous V256V mutation-positive control, 
and oscillating blue peaks (corresponding to a G allele) were seen when a wild type 
control sample was tested. The V256V mutation was thus detected by partially-
denaturing conditions using dHPLC analysis for the purposes of this project.  
 
Detection of the G863A mutation was attempted using an AS-PCR assay. Due to the 
small difference in size between the amplified wild type and mutant alleles (10bp) the 
products generated from the AS-PCR were visualised using size-based separation by 
dHPLC analysis.  
 
Similarly, detection of the R152X mutation was also attempted using an AS-PCR assay. 
The designed AS-PCR primers resulted in a 24bp product difference between the wild 












observed in this assay, even after numerous optimisation procedures were attempted, 
including the use of 3’ LNA residues in the primers. The R152X mutation was 
consequently detected by partially-denaturing conditions using dHPLC analysis. 
However, the R152Q (c.455G>A) variant next to the R152X (c.454C>T) mutation site, 
created an aberrant dHPLC chromatogram profile identical to that of the positive 
control. As a result, all samples exhibiting aberrant dHPLC profiles of exon 5 needed to 
be sequenced in order to determine the true nature of the sequence variant. Literature 
reports revealed that previous researchers have classified the R152Q as a rare sequence 
variant, due to the fact that it was found to occur at similar frequencies in both a control 
and patient cohort (Rivera et al. 2000). 
 
For future laboratory work involving AS-PCR primer design, the incorporation of a 
mismatch either one, two or three nucleotides, 5’ of the mutation of interest, should be 
considered, as this has been found to improve allele discrimination (Kwok et al. 1994). 
Furthermore, in order to aid in the size-based differentiation between wild type and 
mutation-containing alleles, longer random nucleotide tails should be incorporated on 
the 5’ end of either one of the allele-specific primers. In the case where random 
nucleotides are incorporated on both allele-specific primers, the length of the tails should 
vary enough between the two primers in order for adequate allele discrimination. 
 
In designing methods for dHPLC analysis, one should be aware of the fact that 
alterations in the sequence that are found to be in close proximity to the mutation site of 
interest could interfere with result analysis. Therefore results from mutation analysis 
performed under partially-denaturing conditions using dHPLC analysis should be 
verified by cycle sequencing. 
 
G863A and R152X AS-PCR primers were available lab resources and were thus used 
for this project. Ideally, the V256V, G863A and R152X mutations should be 
incorporated into the SNaPshot multiplex assay. Recently, subsequent to the completion 
of the benchwork of the current project, the detection of the V256V mutation by 












successful. In addition, attempts are currently in progress to incorporate the detection of 
the G863A and R152X mutations, into the multiplex SNaPshot reaction. 
 
4.2 ABCA4 mutations in South Africa 
 
4.2.1 ABCA4 mutation screening in a patient cohort 
 
In the present study, DNA samples from 72 unrelated patients affected with AARs, and 
not previously analysed with the ABCR400 microarray, were screened using the 
designed assay. Of the 72 individuals in the patient cohort, 70 were clinically diagnosed 
as having STGD and two individuals were diagnosed as having CRD. At least one of the 
seven ABCA4 mutations was detected in 50 (69.44%) individuals in the patient cohort; 
this included 28 (38.89%) individuals in whom two mutations were identified (i.e. were 
completely characterised). In agreement with previous studies, the majority of these 
patients (n = 23) were compound heterozygotes. In order to calculate the predicted 
proportion of individuals expected to be fully characterised, the results obtained from the 
ABCR400 microarray chip screening were used as a reference: 100 of 181 (55.25%) 
patients tested with the microarray were found to be completely characterised, of which 
66 of 100 (66%) were found with two of the seven common mutations (unpublished 
data). One would thus expect 36.3% (0.55 x 0.66) of the cohort screened in this study to 
carry two of the seven ABCA4 mutations. The results obtained in this current study are 
therefore in agreement with what was expected.  
 
C1490Y was found to be the most frequently occurring mutation, detected in 14 
(19.44%) patient samples. This mutation was also found to be the most commonly 
occurring in the September et al. (2004) study, as well as in the ABCR400 microarray 
analysis (unpublished data), where the majority of the patient cohorts were affected with 













Of the seven ABCA4 mutations, the R152X and G863A mutations occurred least 
frequently; each was seen in seven (9.72%) patient samples. These mutations were also 
found to be the least commonly detected in the September et al. (2004) study, as well as 
in the ABCR400 microarray analysis (unpublished data). These two mutations are 
therefore the least commonly occurring mutations of the seven screened for in the South 
African STGD cohort. 
 
The frequency of IVS38-10T>C in the current study (15.3%) was in accordance with 
results from the ABCR400 microarray screening, which detected a frequency of IVS38-
10T>C mutations of almost 16%.  
 
As discussed by September et al. (2004), the majority of the six common ABCA4 
mutations detected in their study were found to occur at a higher frequency in the South 
African population in comparison to populations in Europe, with the exception of the 
G863A mutation, which appears to have a founder effect in The Netherlands. As 
mentioned previously, September et al. (2004) classified IVS38-10T>C as non-disease-
causing and it was only detected in 1/64 (1.56%) of patients with arSTGD. In the Rivera 
et al. (2000) study, IVS38-10T>C (identified as a rare sequence variant) was detected at 
a higher frequency, in 9/144 (6.25%) patients with arSTGD in the German population.  
 
Investigations into the spectrum of ABCA4 mutations in the Italian population also 
revealed a very low or non-existent frequency of the seven mutations, with only the 
V256V mutation detected in 1/71 (1.41%) patient samples (Passerini et al. 2009).   
 
An investigation of ABCA4 in 144 German patients affected with STGD identified three 
of the seven common mutations i) G863A, ii) R152X, and iii) V256V, of which G863A 
was detected most often - occurring in 17/144 (11.81%) patient samples (Rivera et al. 
2000). The other two mutations were detected at much lower levels, i.e. 0.69%. The 
results obtained from the current study are thus in agreement with the conclusions drawn 
by September et al. (2004) that apart from G863A, these commonly occurring mutations 













4.2.2 ABCA4 mutation screening in a control cohort 
 
Screening of a total of 269 individuals in a control cohort using the designed assay 
resulted in the detection of a heterozygous mutation in 12 samples (4.46%). Four 
mutations (4%) were detected in a general Caucasian sub-cohort and eight mutations 
(4.73%) were detected in the Afrikaner-specific sub-cohort. The results obtained from 
the control cohort screening indicate that the carrier frequency of the C1490Y, R602W, 
and G863A mutations is slightly higher in comparison to the other mutations (L2027F, 
V256V, and R152X), with the IVS38-10T>C mutation not being detected at all. The 
identification of 12/269 heterozygotes in the control cohort resulted in a background 
frequency of carriers in this population to be 4.46 per 100 individuals (approximately 
5% of South African individuals were found to be carriers of one of the seven ABCA4 
mutations screened for in the present study). This is greater than previous reports, 
estimating the carrier frequency to be between five and 10% for all mutations tested for 
on the ABCR400 microarray (Jaakson et al. 2003). In the current study, half the number 
of heterozygotes was detected in the Caucasian sub-cohort in comparison to the 
Afrikaner sub-cohort. One may therefore gauge that STGD occurs at a relatively high 
incidence in the Afrikaner population. However, percentage-wise this is not the case, the 
Caucasian cohort (n = 100) is almost half the size of the Afrikaner-specific cohort (n = 
169). In addition, the Caucasian sub-cohort is likely to contain some individuals of 
Afrikaner descent. If the Caucasian sub-cohort had consisted only of individuals of 
British or English heritage, it is possible that an even higher difference in frequency 
between the two sub-groups could have been observed. Despite this, the results obtained 

















4.3 Genotype-phenotype correlation 
 
The large amount of ABCA4 allelic and phenotypic heterogeneity has led to 
investigations of a genotype-phenotype model. Numerous investigations have attempted 
to determine the exact relationship between the different ABCA4 mutations and the 
severity of RDD. In 1998, Van Driel et al. stated that most ABCA4 mutations could be 
placed into different classes of severity, and that phenotype can vary depending on the 
remaining total activity of the ABCA4 protein. Alleles which result in a non-functional 
protein have been associated with a more severe RDD phenotype, namely arRP, whereas 
alleles which result in partial ABCA4 activity have been associated with milder RDD 
phenotypes, namely CRD and STGD. Valverde et al. (2006) hypothesised that both the 
type of mutation and its position, in conjunction with the paired combination of disease-
causing ABCA4 variations, play a role in the AOO of visual impairment or deterioration. 
Similarly, Lewis et al. (1999) used the AOO of visual impairment to assess the clinical 
severity of a paired combination of mutations.  
 
4.3.1 Investigating the pathogenicity of ABCA4 mutations 
 
In order to assess the effect that each of the seven ABCA4 mutations has on the ABCA4 
protein function, pathogenicity predictions were assigned to each mutation using 
bioinformatic tools and an extensive literature search. It was thought that determination 
of the pathogenicity of the mutations could aid in the understanding of the genotype-
phenotype correlation. Due to the fact that four (C1490Y, R602W, L2027F, and G863A) 
of the mutations were missense mutations, one (R152X) a nonsense mutation, and the 
other two (V256V and IVS38-10T>C) possible splice site mutations, different 
bioinformatic tools were used to investigate the possible biological consequence of the 
mutations. Predicted pathogenicity for each mutation was assigned according to the 
results obtained. Overall predictions revealed the C1490Y mutation to be the most 
pathogenic, whereas the IVS38-10T>C mutation was predicted to be the least 












ABCA4 mutations was as follows: C1490Y, R602W, V256V, R152X, G863A, L2027F, 
and IVS38-10T>C. 
 
Previous research revealed that a large proportion of the patients found to carry the 
C1490Y mutation presented with an earlier AOO (i.e. 11 years) in comparison to 
patients with no C1490Y mutation (September et al. 2004). Functional analysis has 
revealed that the presence of a C1490Y allele decreases the amount of ATP hydrolytic 
activity and causes mislocalisation of the ABCA4 protein to the inner segment (and not 
the outer segment) of the photoreceptor (Wisznieski et al. 2005). It is therefore plausible 
that C1490Y could be predicted to be highly pathogenic. The R602W mutation has also 
been shown to interrupt ABCA4 localisation in a similar way to C1490Y. Mutations 
affecting protein localisation were predicted to have greater pathogenicity in comparison 
to both splice-site mutations and mutations resulting in protein truncation. 
 
The BDGP Splice Site Prediction programme, used to evaluate the intronic IVS38-
10T>C mutation, did not detect any change in splicing of exon 39 in ABCA4. Rivera et 
al. (2000) investigated the functional effect of the IVS38-10T>C alteration by means of 
an Exon Trapping System (pSPL3b), which is a plasmid that consists of β-globin coding 
sequences that are of rabbit or gin and are separated by a fragment of the HIV-tat gene 
which is present in humans (Burn et al. 1995). The wild type and mutant clones 
consisting of IVS38-10T>C were transfected into COS7 cells (Rivera et al. 2000); cell 
lines derived from monkey kidney cells. The mRNA was isolated from the cells and 
analysed using reverse-transcription (RT)-PCR. The results obtained revealed no 
difference in the product size of exon 39 and no exon 39 skipping between the wild type 
and mutant clones. In an alternate assay, Rivera et al. (2000) conducted further RT-PCR 
analysis using RNA obtained from an Epstein-Barr virus-transformed lymphoblastoid 
cell line from one of the patients found to be heterozygous for the mutation. These 
findings were in agreement with the previous results obtained using COS7 cell lines as 
well as with the result obtained from the BDGP Splice Site Prediction programme in the 
current study. Despite the fact that IVS38-10T>C is situated at the – 10 nucleotide 












exon 39. However, investigations into whether or not the wild type nucleotide is 
conserved amongst various species revealed 100% conservation, which could thus 
indicate the value of a wild type allele with no IVS38-10T>C alteration. Even though 
IVS38-10T>C was not found to affect the splicing of exon 39, it is possible that it could 
affect splicing of another exon in ABCA4. It may, however, not be a mutation and 
instead be in linkage disequilibrium with a mutation that has yet to be identified. But, if 
IVS38-10T>C is indeed a mutation, it could affect splicing of another exon or it could 
affect the ABCA4 protein some other way, acting as an enhancer or playing a role in 
methylation (Dr. R. Allikmets, personal communication). A recent study, conducted by 
Schindler et al. (2010) investigated the pathogenic contribution of recessive ABCA4 
alleles. The researchers found that disease-causing ABCA4 alleles carrying the IVS38-
10T>C mutation were one of the most common alleles in the cohort investigated had a 
severe effect on patients’ visual acuities and visual fields. However, due to the fact that 
the function of this mutation could not be definitively determined, IVS38-10T>C was 
given the lowest pathogenicity score in comparison with the other six ABCA4 mutations. 
If and when the exact nature and function of IVS38-10T>C, and its true pathogenicity is 
determined, its placement relative to the other six mutations analysed here may be 
reconsidered.  
 
4.3.2 Statistical analysis 
 
Due to the presence of a relatively large cohort of individuals with two disease-causing 
ABCA4 variations, statistical analysis was conducted in the current study in order to 
further investigate the proposed genotype-phenotype model. As mentioned earlier, in 
other investigations into the relationship between the different ABCA4 mutations and the 
severity of RDD, AOO was used as a measure of phenotype. AOO of the disease was 
the only clinical data available for the majority of the individuals in the current study, 













The results obtained from the ABCR400 microarray chip screening and subsequent 
family studies identified 86 individuals from 66 families with two ABCA4 mutations. 
Reasonable clinical data with a clear AOO of the disease was available for 80 of the 
individuals. The results obtained from screening of the seven ABCA4 mutations in this 
current study identified 28 patients with two mutations. The AOO was available for 26 
of these individuals. This amounted to a total cohort of 106 individuals from 94 families 
on whom statistical analysis could be conducted and included a total of 23 different bi-
allelic mutation combinations.  
 
Although a variety of different mutation combinations of the ABCA4 mutations were 
identified in the combined cohort, a relatively small number of individuals were 
identified for each genotype. Due to the types of statistical tests conducted on the data - 
the Kruskal-Wallis test and the Wilkoxon Rank Sum test – only certain mutation 
combinations were included in the analysis, resulting in fewer individuals being 
included in the final analyses. For the Kruskal-Wallis test, mutation combinations 
consisting of five or more individuals were included in the analysis. This resulted in a 
total of 76 individuals and a total of nine mutation combinations being included in the 
analysis. For the Wilkoxon Rank Sum test, mutation combinations consisting of three or 
more individuals were included for this analysis. This resulted in a total of 97 
individuals and a total of 16 different mutation combinations being included in the 
analysis. 
 
Statistical analysis using the Kruskal-Wallis test revealed a significant difference 
between the mutation combinations (genotype) and the AOO of disease in the patient 
cohort. When this result was investigated further using the Wilkoxon Rank Sum test, in 
order to determine which two paired mutation combinations of ABCA4 mutations 
(genotype) were significantly different, 37 different paired combinations were shown to 
be significant. However, when the Bonferroni correction for multiple testing was 
performed, due to the large number of tests conducted (n = 120), no significant 












4.3.3 Analysis of the genotype-phenotype model 
 
Inspection of the average AOO observed amongst the various mutation combinations, 
revealed that individuals who were found to carry one of the four most highly predicted 
pathogenic mutations (C1490Y, R602W, V256V, and R152X - in decreasing order of 
predicted pathogenicity) was found to be between six and 12 years of age. Thus, due to 
the early AOO, these four mutations do appear to be more pathogenic in comparison to 
the other three mutations. 
 
An interesting observation in the present study is that patients found to carry at least one 
C1490Y mutation had an AOO of 20 years and less. This is in agreement with the 
findings of September et al. (2004), who also found individuals carrying a C1490Y 
mutation had an AOO of less than 20 years. Furthermore, this is also in agreement with 
the pathogenicity analysis which revealed this variant to be the most pathogenic. 
 
Although the IVS38-10T>C was predicted as the least pathogenic, due to the fact that its 
function is still unknown, this mutation was detected in 23 patients, two of whom were 
found to be homozygous. In addition to this, the average AOO was found to range from 
six to 11 years of age, except for one individual (AOO = 20 years) who was found to 
carry a single G863A mutation of her other allele. These results indicate the possibility 
of this mutation being incorrectly placed as the least pathogenic of the seven mutations, 
and this might need to be re-assessed.  
 
In the current study, three patients within the same family (Family 9) were found to have 
a relatively late AOO of disease, of between 30 and 36 years of age. All three patients 
were found to be compound heterozygotes for the G863A and R152X mutations. The 
AOO in these three patients is much later in comparison to individuals carrying a 
C1490Y mutation. It has been noted previously that an individual with a R152X 
mutation on one allele has only one functional allele remaining (Zhang et al. 1999). 












transmitted on different alleles (i.e. “in trans”). Therefore the G863A mutation on the 
functional allele may be responsible for the later AOO observed in these patients. The 
later AOO, however, may not be solely due to the two ABCA4 mutations themselves, but 
may involve as yet unidentified genetic and/or environmental modifiers specifically 
occurring in this family.  
 
Interestingly, although only a small group (n = 12), all patients who were found to carry 
a G863A mutation had a later AOO. No homozygotes were detected; however, the 
results obtained thus far are in accordance with the literature and previous investigations, 
which suggested G863A has a mild effect on ABCA4 protein activity. This mutation 
was placed as the fifth highest pathogenic mutation. In addition, in most cases, 
individuals with an L2027F mutation, although not as delayed, were also found to have a 
slightly later AOO. One homozygote was detected for this mutation, and was shown to 
have an AOO of 28 years. This mutation was placed as the sixth highest pathogenic 
mutation. Based on what has been discussed, it is possible that that the G863A mutation 
is actually less pathogenic in comparison to L2027F. Nevertheless, in agreement with 
the pathogenicity predictions, these two mutations do appear to be less pathogenic in 
comparison to C1490Y, R602W, V256V, and R152X. 
 
September et al. (2004) identified a patient who was a compound heterozygote for the 
V256V and R152X mutations. The disease phenotype for this individual was reported to 
change over time from STGD to a more severe phenotype, arRP. This was not the case 
for the three patients identified by the ABCR400 microarray screening who were also 
found to be compound heterozygotes for the V256V and R152X mutations, but whose 
disease phenotype remained STGD. However, adequate ophthalmologic data was not 
available for these three patients in order to conduct further analysis. 
 
A change in disease phenotype from CRD to the more severe arRP phenotype was, 
however, observed for two patients who were shown to carry two different mutation 












heterozygote for the C1490Y and V256V mutations, whilst the other, RP 428.1IGN, was 
found to be a compound heterozygote for the C1490Y and R602W mutations. This 
observation of C1490Y, albeit in a relatively small subset of re-classified patients, does 
support the previous predictions of its pathogenicity. 
 
The re-classification or progression of disease phenotype from STGD to CRD was 
observed in three individuals who were also identified as having two of the seven 
mutations. Individual RPS 165.2IZA was found to be a compound heterozygote for the 
C1490Y and V256V mutations (same mutation combination as individual RPM 
303.2EBE, discussed above). Individual RP 442.2HUG was found to be a compound 
heterozygote for the C1490Y and IVS38-10T>C mutations. Individual RPM 518.2JAR 
was found to be compound heterozygous for the IVS38-10T>C and R152X mutations. 
These individuals had AOO varying from five to 15 years. It is possible that these three 
mutation combinations are associated with the development of an AAR at an earlier age, 
however, more individuals per mutation category are required in order to test this 
assumption more effectively. As all three individuals were shown to carry different 
mutation combinations, one could not assess the exact mutation or mutation combination 
responsible for the progression of disease phenotype from STGD to CRD. 
 
One individual in the patient cohort was shown to be homozygous for the V256V 
mutation (RPS 133.4CHA). September et al. (2004) noted the V256V mutation could 
have a severe effect on the ABCA4 protein, being associated with arRP and resulting in 
an earlier AOO. The AOO for this patient was eight years. Since the patient was shown 
to carry two “severe” V256V mutations, an early AOO was not surprising. Due to the 
severe nature of this mutation, the fact that it had been previously associated with arRP 
and the fact that the individual carried two copies of this mutation, it could have been 
expected that the individual would develop arRP, a more severe AAR. However, this 
individual was confirmed to have STGD and not arRP. Research has shown phenotype 
variability between individuals even from the same family. This could be a sign of 












of an ABCA4 genotype (Ernest et al. 2009). Therefore, it is important to revisit all 
patients in order to follow up on the reclassification of patient phenotypes. 
 
As mentioned earlier, previous research defining the relationship between the various 
ABCA4 mutations detected, and the resulting retinal disease has been limited by a 
variety of factors. Attempts at defining the genotype-phenotype correlation have been 
restricted by: i) the limited number of families with the same mutations, ii) the limited 
number of families with the same combination of mutations for comparison, and iii) 
inadequate phenotypic or ophthalmologic data. The combined screening results obtained 
from this current study and from previous microarray screening revealed a total of 23 
different mutation combinations that were identified amongst a total of 106 individuals 
(who had a specified AOO) in the patient cohort. This was seen as a large group on 
which to conduct statistical analysis, however, very few individuals were detected with 
the same mutation combination, resulting in some mutation combinations being 
excluded from the data analysis. This had an effect on the strength of the analysis. If 
more individuals had been identified with the same mutation combination and were also 
found to have a self-reported AOO, this could have aided in increasing the strength of 
the statistical analyses. It is also important to note that investigations into the effect of 
the mutations independently, as well as the effect of each mutation in combination with 
one another, could also prove to be essential in order to understand the biological effect 
they could have on an individual’s phenotype. 
 
4.4 Concluding remarks and future plans 
 
The assays designed for this project utilise the existence of seven common ABCA4 
mutations in the South African population, specifically in those individuals of Afrikaner 
descent, and may be employed in the future to target or direct testing for both research 
and diagnostic purposes. These mutations had a pick-up rate of approximately 40% in 












laboratory and patient. It is important to note, however, that both the ABCR400 
microarray and the present analysis were not screening for previously uncharacterised 
mutations (i.e. through re-sequencing). Although the seven mutations were found in a 
large percentage of South African patients, in the future novel variants might also be 
found to be diseasing-causing in a large proportion of individuals. Therefore, it is 
possible that these seven mutations may not be the only relatively common ABCA4 
mutations in the South African population. 
 
Ideally it would have been more beneficial to design one assay to screen for all seven of 
the common ABCA4 mutations. However, due to technical problems encountered in 
trying to create methods to detect some of the mutations and due to time constraints, this 
was not accomplished. Future work could therefore involve creating the single multiplex 
diagnostic assay, in order reduce i) the required labour time, and ii) testing costs for both 
the patient and the laboratory itself. The incorporation of the seven mutations into a 
single test could become appealing in a diagnostic setting, where it could be promoted 
by counsellors, medical geneticists and ophthalmologists to patients as a potential risk 
test (Sohrab et al. 2010). 
 
Previous research has sugge ted the presence of founder mutations in the South African 
population, of mainly Caucasian Afrikaner descent. For this reason the Afrikaner-
specific sub-cohort was of particular interest in the current study. A total of eight 
heterozygous mutations (4.73%) were detected in the individuals of Afrikaner descent, 
with a total of 12 heterozygous mutations (4.46%) being detected in the total control 
cohort. As much as an emphasis was made to recruit “Afrikaner” controls, the Caucasian 
control cohort was not selected on the basis of excluding any “Afrikaner” ancestry, and 
the findings may represent a level of “admixture”. The results from the total control 
cohort indicated the carrier frequency in this particular population to be 4.46 per 100 
individuals. This information can be used in order to assist counsellors in relating risk to 













Future work regarding ABCA4 mutations could involve the investigation of the 
frequencies of these seven mutations in other population groups, such as Mixed 
Ancestry and indigenous Black African, for comparison with the frequencies observed 
in the Caucasian/Afrikaner population. 
 
The presence of founder mutations in the South African population, of mainly Caucasian 
Afrikaner descent, needs to be validated for ABCA4. In order to determine whether the 
ABCA4 mutations are true founder mutations, linkage analysis using microsatellite 
markers and single nucleotide polymorphisms (SNPs) spanning the region of each of the 
seven common ABCA4 mutations may be used in groups of unrelated individuals with 
the same common mutation. If the genotyping results reveal that the mutant alleles of 
unrelated individuals occur on the same genomic haplotype, this would confirm the 
mutation’s founder status. However, this may not have any practical relevance or 
clinical utility. 
 
Although IVS38-10T>C was one of the more commonly occurring mutations detected in 
the patient cohort, its role as a mutation was brought into question when its predicted 
pathogencity was being investigated. Although it has been thought to play a role in 
splicing of the ABCA4 protein, the splice prediction programme and previous studies 
conducted by other researchers indicated that it had no effect on protein activity. It could 
perhaps be in linkage disequilibrium with another ABCA4 mutation which has yet to be 
identified, or it could affect ABCA4 protein function in another way. Due to the 
relatively large size of the ABCA4 gene (50 exons), functional studies could prove 
challenging. Future research on IVS38-10T>C could involve performing a similar 
procedure to that conducted by Burn et al. (1995) using an Exon Trapping System in 
retinal-derived cell lines, instead of in COS 7 cells. This could possibly be used to 
determine the true nature of this variant. However, as mentioned above, previous 
research has not shown any indication that this variant has an effect on protein the 
activity of ABCA4. Although it has previously been proposed that it affects splicing of 
exon 39, it is important to keep in mind that other exons could be involved. A decision 












to be considered. The study by Burn et al. (1995) utilised COS 7 cells; since these are 
cell lines derived from monkey kidney cells, future work using retinal-derived cell lines, 
could be more beneficial. Although these cells might not mimic the human eye, in 
comparison to COS 7 cells, they could provide more insight into the functional 
implication of the IVS38-10T>C variant on the ABCA4 protein.  
 
For a test of genotype versus phenotype, the AOO of the disease was tested against the 
different paired combinations of ABCA4 disease-causing mutations. However, despite 
AOO being the most accessible clinical measure, eight out of 114 individuals were 
excluded from the analysis as they did not have a specified or recorded AOO. 
Insufficient clinical data was found to impede the investigation of the genotype-
phenotype correlation. If the AOO of disease for these eight individuals had been 
available, it may possibly have aided in increasing the strength of the statistical analyses. 
It should be noted, however, that the cohort of 106 patients included in the analyses 
consisted of some related individuals; it is therefore possible that other genetic and 
environmental factors may also influence the AOO of disease. In future, it will be useful 
to obtain consistent clinical information for each affected individual to strengthen the 
power of the statistical analyses, towards a better understanding of the genotype-
phenotype correlation. Screening more affected individuals, particularly unrelated 
patients in order to minimise the effect of any familial factors, and identifying more 
individuals with the same paired combination of disease-causing variations in ABCA4 
may also aid in increasing the understanding of the genotype-phenotype model.  
 
The exact function of each domain of the ABCA4 protein is still being elucidated. 
Recently, research has shown specific interaction of the ECD2 domain with all-trans-
retinal (Biswas-Fiss et al. 2010). Furthermore it was shown that three ABCA4 mutations 
(R1443H, W1408L, and C1488R) significantly alter the structure of the above-
mentioned domain, as well as interfering with its normal functioning with all-trans-
retinal. It is therefore important in the first instance to determine the function of each 
ABCA4 domain, followed by the effect of each mutation on domain functioning. In 












ABCA4 mutations. For example, ophthalmologists could examine patients who have 
mutations known to be involved with protein misfolding and compare their scanning 
results with patients who have mutations known to result in protein truncation. 
Alternatively, ophthalmologists could also examine profile differences between 
homozygote and heterozygote individuals. In addition, choroidal imaging could be 
utilised to visualise the structural changes of the choriocapillaris related to RPE cell 
death (Yeoh et al. 2010). Although these techniques are costly, if they prove to be 
successful in developed countries, in the future they may be applied in emerging nations. 
 
In the current study the presence of a significant cohort of South African individuals 
diagnosed as having STGD, with the same common mutations in various combinations, 
was essential in order to i) improve the understanding of the relationship between 
ABCA4 mutation combination and patient phenotype and ii) develop a relevant model 
algorithm. In future, this may enhance the knowledge regarding the impact of each 
mutation or the specific pathogenic effect of each allele on the ABCA4 protein 
(Schindler et al. 2010). These results may well provide the basis of prognosis 
information to patients, thereby enhancing the clinical utility of identifying ABCA4 
mutations.  
 
Until treatment options for AARs become available, recommendations that may limit the 
progression of these diseases include advising affected individuals to: i) limit their 
exposure to direct sunlight, and ii) avoid the intake of Vitamin A-containing products, as 
it is Vitamin A’s derivatives that accumulate when the ABCA4 gene is defective (Sohrab 
et al. 2010).  
 
Finally, the recent RPE65 clinical trials for Leber’s Congenital Amaurosis have been 
well publicised and could provide the link to possible ABCA4 clinical studies 
(Bainbridge et al. 2008; Smith et al. 2009). However, various factors need to be 
considered for clinical studies, such as the criteria for patient selection including i) a 












level of genetic heterogeneity of the individuals included, i.e. the particular the genotype 
inclusion or exclusion criteria (Fishman 2005; Cideciyan et al. 2009). In addition, 
understanding the progression of vision loss in patients with ABCA4 mutations by 
assessing the loss of sensitivity in both rod and cone cells could also play a vital role in 
potential therapeutic approaches (Cideciyan et al. 2009). The RPE65 clinical trial 
requirements and findings could aid in the selection of patients for future ABCA4-related 
studies. A clinically and molecularly defined cohort of patients will therefore be useful 
for ABCA4-gene replacement therapies. A gene-based therapy for STGD, known as 
StarGen, involves the use of a LentiVirus vector system, and is currently being 
investigated by the National Neurovision Research Institute in collaboration with Oxford 
Biomedica (http://www.oxfordbiomedica.co.uk). The initiation of the patient clinical 
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Appendix 1: DNA consent form 
 
REQUEST FOR MOLECULAR STUDIES (DNA) BLOOD FORM 
DIVISION OF HUMAN GENETICS, WERNHER & BEIT NORTH 
FACULTY OF HEALTH SCIENCES, UNIVERSITY OF CAPE TOWN, OBSERVATORY, 7925 
TEL: 021 406-6299   FAX:  021 406-6826  EMAIL: jacquie.greenberg@uct.ac.za 
SURNAME:   ___________________________________     NAME: ________________________________ 
             Mother:  
DATE OF BIRTH:  ____/ ____/_____  DETAILED ETHNIC ORIGIN: Father:_____________________________ 
 
NEW FAMILY:  YES -  NO -  (If NO please fill in family name) FAMILY NAME: ___________________   
 
SEX: FEMALE -   MALE -   Number of Children ___ Number of affected family members: ___ 
 
CONTACT ADDRESS: ____________________________________________________________________ 
  
__________________________________________________________________________CODE _______ 
TEL: …………………...    FAX: ……………………  E-mail ……………………………………………. 
 
NAME OF REFERRING DOCTOR: ____________________ HOSPITAL: _____________________ 
FAX: ____________________ TEL___________________E-mail: ___________________________ 
ADDRESS: ______________________________________________________________________ 
 
REASON FOR REFERRAL  (CLINICAL DIAGNOSIS): 
AFFECTED       AT RISK        CARRIER        SPOUSE         QUERY         UNAFFECTED    
RETINITIS   PIGMENTOSA     USHER SYNDROME            DOMINANT INHERITANCE     
STARGARDT DISEASE           MACULAR DYSTROPHY      DOMINANT INHERITANCE     
ARMD – WET                               ARMD – DRY                      RECESSIVE INHERITANCE        
OTHER DISORDER: AGE OF ONSET: 
DIAGNOSIS AGE: 
X-LINKED INHERITANCE        
        ISOLATED CASE                   
ADDITIONAL FAMILY HISTORY __________________________   Pedigree on separate page please     
 
ADDITIONAL DISORDERS (APPARENT OR PREVIOUSLY TREATED):  _______________________________ 
    
RELEVANT CLINICAL DETAILS: __________________________________________________________ 
 
PHYSICAL DISABILITY         MENTAL RETARDATION            DEAFNESS           IMPAIRED VISION          
NIGHT BLINDNESS                AGE OF ONSET: _____                      OTHER:  ______________________________          
 
Have samples from this patient been sent to a DNA lab before?   Yes / No   / Don't Know.  If “Yes”, Where: 
_______  
Medical Aid ______________________________________ Medical Aid No.__________________________ 
 
For Laboratory use only: DNA number: __________________       Vol.Blood: ____________________ (ml)            
 















 SPECIMEN TUBES REQUIRED:  2 X 4 ml Plastic purple top tubes (containing EDTA)  
NAME AND DATE OF BIRTH TO BE ON EACH TUBE 
 
BLOODS ARE TO BE KEPT REFRIGERATED.  SPECIMENS ARE TO BE CAREFULLY PACKAGED AND            
TRANSPORTED IN A POLYSTYRENE COOLBOX WITH AN ICE BRICK. DO NOT FREEZE. 
 
COURIER SERVICES CAN BE ARRANGED BY THE DIVISION OF HUMAN GENETICS UPON REQUEST   
  
BLOODS ARE CODED ON ARRIVAL IN LABORATORY ACCORDING TO FAMILY NAME 
 
RESULTS ARE GIVEN TO PARTICIPANTS ACCORDING TO ESTABLISHED PROTOCOL WHEN AVAILABLE 
         
CONSENT FORM REQUIRED FOR DNA ANALYSIS AND STORAGE 
 
PLEASE DELETE DETAILS THAT ARE NOT APPLICABLE: 
 
1.    I, ______________________________________, request that an attempt be made using genetic material to assess                                                                              
        the probability that, I / my child / my unborn child, might have inherited a disease-causing mutation in the gene for: 
                 
        ( Name of Disorder): 
2.    I understand that the genetic material for analysis is to be obtained from: blood cells / skin sample  / other (specify)  
3.   I request that no portion of the sample be stored for later use.                                (MARK IF APPLICABLE) 
        OR    I request that a portion of the sample be stored indefinitely for:                            (DELETE WHERE NOT APPLICABLE) 
                   (a) Possible re-analysis 
                   (b) Analysis for the benefit of members of my immediate family 
                   (c) Research purposes, subject to the approval of the University of Cape Town Research Ethics Committee,   
                        provided that any information from such research will remain confidential   
4.   The results of the analysis carried out on this sample of stored biological material will be made known to me, via my    
       doctor, in accordance with the relevant protocol, if and when available. 
             In addition, I authorise that these results may be made known to:                                  (DELETE WHERE NOT APPLICABLE) 
       Doctor’s name or other doctors involved in my care: _______________________________________________ 
       Names of family members: ___________________________________________________________________  
       Other persons: _____________________________________________________________________________ 
 
5.   I authorise / do not authorise my doctor(s) to provide relevant clinical details to the Division of Human Genetics, UCT.                                                                                      
6.   I have been informed that:  
 There are risks and benefits associated with genetic analysis and storage of biological material and these have been              
         explained to me.  
 The analysis procedure is specific to the genetic condition related to the visual impairment mentioned above and cannot 
determine the complete genetic makeup of an individual.  
 The genetics laboratory is under an obligation to respect medical confidentiality. 
 Genetic analysis may not be informative for some families or family members. 
 Even under the best conditions, current technology of this type is not perfect and could lead to incorrect results. 
      Where biological material is used for research purposes, there may be no direct benefit to me. 
7.  I understand that I may withdraw my consent for any aspect of the above at any time without this affecting my future  
     medical care. 
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND, AS WELL 
AS THE QUESTIONS THAT WERE ANSWERED BY:  ________________________________________        
DATE   _______  /_____  /____                                                    PLACE:  ___________________________________                 
PATIENT’S SIGNATURE: _________________________               WITNESS CONSENT: __________________________    














Appendix 2: Reagents, buffers and protocols 
 
10x TBE buffer (stock): 
216g (0.89M) Tris (B&M Scientific cc, Cape Town, SA) 
110g (0.89M) Boric Acid (ICN Biomedicals Inc., USA) 
14.8g (0.04M) EDTA (BDH Electron
®
 Laboratory Supplies, UK) 
Made up to 2L with dH2O  
 
1x TBE buffer (working stock): 
A 10 X dilution of the TBE buffer (stock) was made up using dH2O 
 
1% agarose gel (100ml): 
1g agarose (Lonza, Seakem® LE, Rockland, USA) 
100ml 1 x TBE 
6µl (10mg/ml) EtBr (Sigma-Aldrich, USA) 
 
1.5% agarose gel (100ml): 
1.5g agarose  (Lonza, Seakem® LE, Rockland, USA) 
100ml 1 x TBE 
6µl (10mg/ml) EtBr (Sigma-Aldrich, USA) 
 
2% agarose gel (100ml): 
2g agarose  (Lonza, Seakem® LE, Rockland, USA) 
100ml 1 x TBE 
6µl (10mg/ml) EtBr (Sigma-Aldrich, USA) 
 
Loading Dye: 
0.125g (0.25%) Bromophenol blue (Merck KgaA, Germany) 
40g (40% w/v) sucrose (Merck Pty Ltd., SA) 
pH 8.0 












Molecular weight marker: 
GeneRuler™ 100bp DNA Ladder Plus (Fermentas Life Sciences, Hanover, USA): 
25μl molecular weight marker stock solution 
225μl SABAX dH2O (Adcock Ingram, Johannesburg, SA) 















 size standard  












Alternative PCR purification procedure used for exon 5 (V256V) PCR 
products 
General procedure for NucleoFast 96 PCR (Machery-Nagel AgmH & Co. 
KG, Düren, Germany) - April 2008/Rev. 03 
Standard protocol for the purification of PCR products under vacuum: 
(Designed for PCR reaction volumes of between 20-100μl) 
1. PCR products are transferred to the NucleoFast 96 PCR plate. 
2. PCR contaminants are removed by ultrafiltration. This is performed by placing 
the NucleoFast 96 PCR plate on a suitable vacuum manifold where a vacuum is 
then applied. A typical vacuum has to be applied for 10-15 min for a PCR 
product volume of 50-100μl. Once the products have passed through the plate 
completely, the vacuum is applied for an additional 30-60 seconds. 
3. Vacuum is released for 60-90 seconds, a volume of 100μl of RNase-free dH2O is 
dispensed into each well on the plate and the vacuum is applied until the water 
has passed through the membrane. Thereafter the vacuum is applied for an 
additional 30-60 seconds. (This is an optional wash step).  
 
Ethanol precipitation protocol used for cycle sequencing purification: 
1. A volume of 2µl sodium acetate (3mM, pH5.5) was added to the sequencing 
product. 
2. A 2 X volume of absolute ethanol (Merck Chemicals (Pty) Ltd, Gauteng, SA) 
was also added. 
3. This was followed by an incubation period at -20°C for more than 30 min. 
4. The samples were then centrifuged at 10 000 revolutions per minute (rpm) for 10 
min. 
5. The supernatant was removed. 
6. A 2 X volume of cold 70% ethanol was added to the tubes. 
7. The samples were then centrifuged at 10 000rpm for 10 min. 
8. The supernatant was removed. 
9. The samples were then air-dried for approximately 60 min. 















Appendix 3: Sequence annotations of the seven exons 
interrogated in the study 
 
The exonic regions are written in capital letters, whereas the intronic regions are written 
in lower case. 
The external primary PCR primers (sense and antisense) are highlighted in pink. 
The AS-PCR primers (excluding random nucleotide tails) are indicated by the bold 
nucleotides. 
The internal Snapshot primers (excluding random nucleotide tails) are underlined. 
The mutations are indicated by the bold red font. 
 
Exon 5  
PCR amplicon size: 230 bp  
The c.454C>T (R152X) mutation is indicated by the bold red font. 
 





          exon 5 antisense primer 
 
Exon 6  
PCR amplicon size: 294 bp  
The c.768G>T (V256V) mutation is indicated by the bold red font. 
 



















Exon 13  
PCR amplicon size: 267 bp  
The c.1885C>T (R602W) mutation is indicated by the bold red font. 
 






exon 13 antisense primer 
 
Exon 17  
PCR amplicon size: 232 bp 
The c.2588G>C (G863A) mutation is indicated by the bold red font. 
 





exon 17 antisense primer 
 
Exon 30  
PCR amplicon size: 286 bp  
The c.4469G>A (C1490Y) mutation is indicated by the bold red font. 
 



















Exon 39  
PCR amplicon size: 245 bp  
The c.5461-10T>C (IVS38-10T>C) mutation is indicated by the bold red font. 
 





                                                                                             exon 39 antisense primer 
 
Exon 44  
PCR amplicon size: 287 bp  
The c.6079C>T (L2027F) mutation is indicated by the bold red font. 
 






  exon 44 antisense primer 
 
 
 
 
 
